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ABSTRACT
EXPRESSION AND PURIFICATION OF THE HEPATITIS C VIRUS CORE 
PROTEIN IN E.coli AND TESTING OF HUMAN SERA 
WITH THIS CORE ANTIGEN 
Çağla Eroğlu
M.S, in Molecular Biology and Genetics 
Supervisor: Dr Ergün Pınarbaşı 
July 1998
The hepatitis C virus (HCV) infection is an important cause of morbidity and 
mortality world wide. Infection with HCV becomes chronic in more than 80% of the 
cases and it accounts for 20%of all cases of acute hepatitis. Hepatitis C virus was 
first identified by the molecular cloning of the virus genome in 1989. It is an 
enveloped, positive strand RNA virus with a genome size of around 9.5 Idlobases. 
The single stranded RNA genome of the virus contains a large open reading frame 
codes for a large poly-protein of 3,010 to 3,033 amino acids which is shown to be 
processed by a combination of host and viral proteinases to produce at least ten 
proteins post-translationally. The proteins that are closer to the amino terminal of the 
poly-protein are termed as structural and the rest closer to the carboxy terminal are 
called non-structural (NS) proteins. The core protein is the putative nucleocapsid 
component of the virion, and it is highly basic in nature. Core protein is the most 
highly conserved region of the hepatitis C virus open reading frame and it is shown to 
be highly immunogenic. Also, as the core protein is the putative capsid protein of the
m
hepatitis C virus, antibodies against core antigen most probably arise much earlier 
than the antibodies against nonstructural proteins.
In this study, the core protein of the hepatitis C virus was cloned, expressed 
and purified in order to establish an ELISA system to test the human sera with this 
viral antigen. It was shown that in 86% of the patients, diagnosed previously with the 
third generation enzyme immunoassays to be infected with hepatitis C, have 
antibodies against this core antigen. The core antigen gave no false positive results 
when tested with the negative control samples which were found to be Anti-HCV 
negative previously.
Key Words: Hepatitis C virus; Core (nucleocapsid) protein; Cloning, 
Expression in Kcolr, Purification; ELISA.
IV
ÖZET
HEPATİT C VİRÜSÜ CORE PROTEİNİNİN K colf DE EXPRESYONU 
VE SAFLAŞTIRILMASI VE İNSAN SERUMUNUN
BU ANTİJEN İLE TEST EDİLMESİ
Çağla Eroğlu
Moleküler Biyoloji ve Genetik Yüksek Lisans 
Tez Yöneticisi: Dr. Ergün Pınarbaşı
Temmuz 1998
Hepatit C virüsünün (HCV) yol açtığı infeksiyon tüm dünyada önemli bir 
hastalık ve ölüm nedenidir. Vakalann yüzde 80’ninden çoğunda HCV infeksiyonu 
kronikleşir ve bu tüm akut hepatit vakalannm yüzde 20’sini oluştumr. Hepatit C 
virüsü ilk olarak 1989 yılında moleküler klonlama yöntemi ile tanımlandı. Bu zarflı, 
pozitif iplikli, RNA virüsü 9.5 kilobazlık bir genoma sahiptir. Virüsün tek iplikli 
RNA genomu 3.010 ila 3033 amino asitlik büyük bir poli-protein kodlayan geniş bir 
açık okuma çerçevesi içerir. Bu poli-protein, sentezlendikten sonra, hücresel ve viral 
proteinazlar tarafından en azından on аул proteine bölünür. Poli-proteinin amino 
ucuna yakın olan proteinler yapısal, ve diğer, karboksil ucuna yakın olan proteinler 
ise yapısal olmayan diye adlandırılırlar. Core proteininin virüsün çekirdek-kapsül 
bileşeni olduğu düşünülmektedir. Bu protein oldukça baziktir. Core proteini HCV 
genomunun oldukça korunmuş bir bölgesinden kodlanır ve çok iminojeniktir. 
Yapısal bir protein olması nedeniyle, yapısal olmayan proteinlerden çok daha önce, 
antikor tepkisi yaratır.
Bu çalışmada HCV core proteini klonlandı, E-coIfda üretildi ve saflaştınidı. 
Daha vsonra bu viral antijen ile insan serumunda antikor taranması için bir ELISA 
test sistemi oluşturuldu. Bu test sistemi kullanılarak, daha önce üçüncü nesil 
enzimatik immunotest ile HCV enfeksiyonu belirlenmiş hastaların, yüzde 86’sında, 
core proteinine karşı antikor varlığı gösterildi. Daha önce HCV antikorlan 
içermediği gösterilmiş kontrol numuneleri ile bu core antijeni test edildiğinde 
herhangi bir yanlış pozitif netice görülmedi.
Anahtar Sözcükler: Hepatit C virüsü, core antijeni, E.coirdQ protein 
ekspresyonu, protein saflaştırması, ELİSA
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1. INTRODUCTION
1.1 HEPATITIS C VIRUS: EPIDEMIOLOGY AND TRANSMISSION
The hepatitis C viais (HCV) infection is an important cause of morbidity and 
mortality world wide. Infection with HCV becomes chronic in more than 80% of the 
cases and it accounts for 20% of all cases of acute hepatitis. This disease is estimated 
to affect around 100 million people world wide and is characterized by a mild and 
often undiagnosed acute illness which evolves into a persistent infection and 
eventually to liver failure and cirrhosis. Currently, hepatitis C is responsible for an 
estimated 8,000 to 10,000 deaths annually, and without effective intervention that 
number is postulated to triple in the next decade. Epidemiological data also suggest a 
link between the chronic infection and the development of hepatocellular carcinoma. 
The viral genome and antigens have been detected in effected liver cells (Haruna et 
al., 1993). The degeneration of the infected hepatocytes may be caused either directly 
by cytopathic effect of the virus or indirectly by immune responses of the host mainly 
through the function of the CTL. Continuous occurrence of degeneration followed by 
regeneration of hepatocytes, together with the fibrotic changes of the liver tissues, 
would then result in liver cirrhosis, from which hepatocellular carcinoma eventually
arises m some cases.
Hepatitis C is transmitted primarily by the parental route, and sources of 
infection include injection drug use, needle-stick accidents, and transfusions of blood 
or blood products. Since 1990, after the introduction of sensitive and effective blood 
tests for detection of antibodies to HCV (Anti-HCV), new cases of posttransfusion 
hepatitis C have virtually disappeared in the Western world. The risk of the 
transfusion related hepatitis is now in the range of 1 in 100,000 units transfused in 
these countries. Wherever this is not the case in the developing countries. The 
multiple use of syringes and lack of detection tests for the blood donors created a 
drastic increase in the number of people infected with the hepatitis C virus in 
countries such as Egypt and Ukraine. In Turkey detection of antibodies against HCV 
in the blood donors’ sera started in 1997 and estimated to become a routine test in 
the following years. The recent data based on tests made to blood donors in Turkey 
showed that the 1.5% of the population is Anti-HCV positive. The figures for 
Turkey and some other countries are presented on the map in Figure 1.1, (Heintges 
and Wands, et al., 1997).
HCV is transmitted by contaminated needles. This is the basic risk factor for 
the health workers (nurses, doctors, other hospital personnel). The rate of 
transmission probably depends in part on the quantity of blood transferred to the 
recipient by the needle stick, the titer of virus, and the depth of inoculation. 
Approximately 2% of exposed individuals will develop viremia and/or anti-HCV 
antibodies after needle stick exposure. The rate of infection after sticks with solid 
needles appears to be lower as compared with accidents with hollow cannula devices, 
(Alter et al., 1995; Heintges and Wands, et al., 1997).
1.1.1 Risk Groups
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There is a very high prevalence of HCV antibodies among drug abusers 
because of the shared use of contaminated needles and syringes. In most studies, 
HCV exposure and antibody positivity rates have been reported to be higher than 
50% and close to 100% in some populations, (Fingerhood, et al., 1993; Woodfield, 
et al., 1993). It seems logical that the use of disposable syringes will lead to a 
decrease of HCV infection in this population over time.
Chronic HCV infection is also common in hemophiliacs. Previously, more 
than 1000 units of donor plasma was pooled to produce a single lot of clotting 
factors. This mixing of donor plasma, as well as the lack of procedures to inactivate 
potential viral contaminates such as heat inactivation or pasteurization, lead to veiy 
high rates of HCV transmission. Indeed, when hemophiliacs received concentrates of 
clotting factors in which inadequate virus inactivation procedures, the prevalence of 
antibodies to HCV following administration was found to vary between 84% and 
100%, (Mauser-Bunschoten et al., 1995; Morfini et al., 1994). It is now very 
encouraging that hemophiliacs treated with clotting factor preparations that use more 
recent viral inactivating procedures are rarely positive for HCV antibodies. 
Nevertheless, the mean HCV antibody positivity rate is still approximately 76% in 
hemophiliacs (Mauser-Bunschoten et al., 1995).
It is apparent that the modes of transmission for HIV and HCV are similar. 
Therefore dual infection with these two viral agents is common particularly 
intravenous abusing drug addicts. In an unselected group of HIV positive patients, 
approximately 35% were co-infected with HCV.
HCV infection is frequent among patients on chronic hemodialysis. The
prevalence of HCV antibodies varies between 8% to 69%, (Bukh, et al., 1993; Lin et
al., 1993). Individuals with terminal renal insufficiency may be immunocomprimised
4
to variable degrees. Therefore HCV RNA has been found by reverse transcriptase 
polymerase chain reaction in 5% of individuals who are negative for Anti HCV 
antibodies. Indeed, HCV RNA has been detected between 10% and 52% of patients 
on hemodialysis. ALT levels may be normal in approximately 70%, even in the 
presence of viremia. The risk of HCV infection appears to correlate with the duration 
and frequency of hemodialysis (Alter et al., 1995; Heintges and Wands, et al., 1997).
Persistent HCV infection is common in transplant recipients. Studies showed 
that HCV transmission was almost 100% when organs were taken from HCV RNA 
positive donors. It is controversial whether organs obtained from infected donors 
should be used for transplantation. Most investigations have found no significant 
increase in mortality, morbidity in patients who received HCV infected organ 
transplantation (other than liver).
1.1.2 Natural History of Hepatitis C
Data on the natural history of hepatitis C are limited, because the onset of 
infection is often unrecognized and the early course of the disease is indolent and 
protracted in many individuals. The natural history of the disease appears to differ 
according to geography, alcohol use, virus characteristics such as genotype and viral 
load, co-infection with other viruses, and other unexplained factors.
There are three phases of HCV infection; that are acute silent and reactivated. 
After initial exposure, HCV RNA can be detected in blood in one to three weeks. 
Within an average of fifty days (range, 15-150 days), virtually all patients develop 
liver cell injury, as shown by elevation of serum alanine aminotransferase (ALT). The 
majority of patients are asymptotic and anicteric. Only 25% to 35% develop malaise, 
weakness, or anorexia, and some become icteric. Anti-HCV almost invariably
become detectable during the course of illness. Anti HCV can be detected in 50% to 
70% of patients at the onset of symptoms in approximately 90% of patients three 
months after onset of infection. HCV infection is self limited in only 15% of cases. 
Recovery is characterized by disappearance of HCV RNA from blood and return of 
liver enzymes to normal (Hoofnagle and Tralka, 1997).
Hepatitis C virus is not easily cleared by the host’s immunological defenses. 
Thus, a persistent infection develops in perhaps as many as 85% of patients with 
acute hepatitis C. This inability to clear the virus by the infected host sets the stage 
for the development of chronic liver disease. The range of disease states after 
hepatitis C infection is broad. Also in contrast to hepatitis A and B, there is no 
effective vaccine to prevent acquisition of hepatitis C infection. As a result 85% of 
HCV infected individuals fail to clear the virus by 6 months and develop chronic 
hepatitis with persistent, although sometimes intermittent, viremia. This capacity to 
produce chronic hepatitis is one of the most striking features of HCV infection. The 
majority of patients with chronic infection have abnormalities in ALT levels that can 
fluctuate widely. Approximately one third of patients have persistently normal serum 
ALT levels. Antibodies to HCV or circulating viral RNA can be demonstrated in 
virtually all patients.
Chronic hepatitis C is typically an insidious process, progressing, if at all, at a 
slow rate without symptoms or physical signs in the majority of patients during the 
first two decades after infection. Less than 20% of the patients with chronic hepatitis 
C, develops nonspecific symptoms, including mild intermittent fatigue and malaise. 
Symptoms first appear in many patients with chronic hepatitis C at the time of 
development of advanced liver disease (Hoofiiagle and Tralka, 1997).
In chronic hepatitis, inflammatory cells infiltrate the portal tracts and may also 
collect in small clusters in parenchyma which is usually accompanied by focal liver 
cell necrosis. The margin of the parenchyma and portal tracts may become inflamed, 
with liver cell necrosis at this site (interface hepatitis). If and when the disease 
progresses the inflammation and liver cell death may lead to fibrosis. Mild fibrosis is 
confined to the portal tracts and immediately adjacent parenchyma. More severe 
fibrosis can lead to cirrhosis that is defined as a state of diffuse fibrosis in which 
fibrous septae separate clusters of liver cells into nodules. The rate of progression is 
highly variable and not always consistent with the serum ALT levels. Chronic 
hepatitis C infection leads to cirrhosis in at least 20% patients within two decades of 
the onset of infection, although in some cases cirrhosis and end-stage liver disease 
may occasionally develop rapidly especially among patients with concomitant alcohol 
use.
Chronic infection by HCV is associated with an increased risk of liver cancer. 
The accepted idea is that hepatocellular carcinoma (HCC) occurs against a 
background of inflammation and regeneration associated with chronic hepatitis over 
the course of approximately three or more decades. Most cases of HCV related HCC 
occur in the presence of cirrhosis.
The risk that a person with chronic hepatitis C will develop HCC appears to 
be 1% to 5% after 20 years, with striking variations in rates in different geographic 
areas of the world. Once cirrhosis is established, the rate of development of HCC 
increases to 1% to 4% per year. Among patients with cirrhosis caused by hepatitis C, 
HCC develops more commonly in men than in women and in older than in younger 
patients.
Hepatitis C patients occasionally present some extrahepatic manifestations or 
syndromes considered to be of immunologic origin, including arthritis, 
keratoconjunctivitis sicca, lichen planus, glomerulonephritis, and essential mixed 
cryoglobulinemia.
After an average follow-up duration of 18 years, a prospective study of 
patients who received blood transfusions showed no difference in overall mortality 
between HCV infected cases and the non-infected controls. Liver related mortality, 
although rare, was twice as high in the cases with HCV infection, (3.2% versus 
1.5%), (Hooftiagle and Tralka, 1997).
1.2 DIAGNOSIS OF HEPATITIS C
Several diagnostic tests have been developed by using two means, serological 
(using recombinant antigens), and molecular (PCR-being used to determine the 
extent of the virus variation). Serological tests that detect anti-HCV include enzyme 
immunoassays (EIAs), which contain HCV antigens from the core and nonstructural 
genes, and the recombinant immunoblot assays (RJBAs), which contain the same 
HCV antigens as EIA in an immunoblot format. Besides, several polymerase chain 
reaction (PCR)-based assays for HCV RNA have been developed to detect the RNA 
virus directly. Also liver biopsy can determine the extent of liver injury caused by 
HCV.
Despite the significant sequence heterogeneity among the HCV isolates, anti-
HCV antibody screening is effective for the prevention of especially post-transfusion
hepatitis C. Soon after the identification and the molecular cloning of the HCV
genome in 1989, the first generation assays using a recombinant fusion protein CIOO-
3 was developed. This C l00-3 antigen was deduced from the junction region of
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nonstmctural proteins 3 and 4 of the prototype HCV (HCV-PT (la)) strain, (Kuo et 
al., 1989). Later, the sequence heterogeneity of the NS4 region was found to cause 
the low detection rate, (Nagayama et al., 1993). To increase efficiency a second 
generation assay was developed. The antigens were part of core, NS3 and NS4 
regions, (Mimms et al., 1990). The major factor that contributed was the core 
antigen, as the nucleotide sequence of the core protein is highly conserved among 
HCV subtypes in contrast to the NS4 region, (Seki et al., 1995).
Currently, the second generation enzyme immunoassays (EIA-2) for anti- 
HCV are the most practical screening tests for the diagnosis of HCV infection 
throughout the world. These assays detect antibodies to recombinant HCV antigens 
from the core (C22) and nonstructural regions 3 (C33) and 4 (C-lOO). They are easy 
to perform and results are highly reproducible. The more recent third generation 
enzyme immunoassay (EIA-3) is also used widely throughout Europe and Asia. EIA- 
3 is slightly more sensitive than the EIA-2, but the sensitivity is mostly from the 
increased detection of anti-C33 rather than the addition of the new antigen from NS5, 
(Lok and Gunaratham, 1997). The second generation recombinant immunoblot 
assays (RIBA-2) permit the detection of antibodies to individual recombinant HCV 
antigens: C22, C33, ClOO, and 5-1-1 (overlaps with C-100). Patients who react to 
two or more HCV antigens are considered to be positive, whereas those who react to 
one HCV antigen only are considered to have indeterminate results. RIBAs are 
technically more demanding than the EIAs but they are simpler, more standardized 
and cheaper than the HCV RNA tests.
The EIA tests are reproducible, inexpensive and automated. They are suitable
for screening low and high prevalence populations and as an initial test for patients
with clinical liver disease. The RIBA test is most frequently used as a supplemental
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assay. Qualitative HCV RNA detection by reverse transcription PCR is generally 
accepted as the most sensitive test, and tried to be standardized. However, still there 
are inconsistencies among different laboratories.
The sensitivity of the second generation enzyme immunoassay, El A-2, is 92% 
to 95%. However it has been shown that El As give a high number of false positives 
among blood donors with no risk of HCV. Only 25% to 65% of the blood donors 
with no risk factors to HCV infection found to be positive for EIA-2 are HCV RNA 
positive. After conformation with a RIBA test this percentage increases to 70% to 
75%. RIBA tests only by themselves give 50% false positive results in the surveys 
among blood donors.
Confirmation of the diagnosis of the ongoing HCV infection relies on the 
detection of viremia. This may be achieved by qualitative reverse transcription PCR 
or branched DNA (bDNA) assays. Although the bDNA assay is technically simpler 
and has a lower chance of cross contamination, PCR assays are preferred for the 
confirmation of HCV infection because of their increased sensitivities. The sensitivity 
is 200 to 400 fold in PCR assays, thus 10% to 30% of the patients with chronic 
hepatitis C who are HCV RNA positive by PCR assays may have undetectable HCV 
RNA if tested by bDNA assay, (Lok and Gunaratham, 1997). However the lack of 
standardization and risk of contamination in HCV RT-PCR techniques, makes this 
technique less reliable than it could be.
In patient who present with biochemical or clinical evidence of liver disease 
(for example repeatedly elevated ALT levels), a positive EIA test is sufficient to 
diagnose hepatitis C infection, especially if the risk factors are present. A qualitative 
HCV RNA test can be used for confirmation. If the patient is being considered for 
antiviral therapy, liver biopsy is of value to assess disease severity.
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Testing of serum ALT levels is the most inexpensive and noninvasive means 
of assessing disease activity. It is also often the first indication that there is something 
wrong in the liver. However a single measurement is not effective and sufficient for 
assessing disease activity. Serial determinations of ALT levels over time may provide 
better means of understanding severity of the underlying liver injury. Nevertheless, 
the resolution of elevated ALT levels with antiviral therapy does appear to be an 
important indicator of disease response, and serial determinations of ALT levels can 
be recommended as the general means of monitoring patients with the disease (Lok 
and Gunaratham, 1997).
1.3 VARIABLITY OF HEPATITIS C VIRUS AND ITS GENOTYPES
Being a rapidly evolving RNA virus extensive variations in the HCV genotype 
has been observed in chimpanzees at rate of around 1.44x10'^ base substitutions per 
site per year from which it can be concluded that with a simple calculation, all the 
nucleotides in the genome of the HCV would mutate after 700 years of infection in 
the chimpanzee. However closer analysis on chimpanzees suggested that the 
variability/stability of the genome varies by region within the genome. Differences 
between nucleotide sequences of various HCV strains where found to be mostly in 
the HVRl and the 3’UTR. In contrast the nucleic acid sequence of 5’UTR is not 
highly divergent as mentioned before. The region which is best suited for genotyping 
is obviously the one that shows identical sequences for isolates belonging to same 
genotype, but clear differences in sequence for those of different genotypes. Still 
today it is debatable that which region of the genome is suitable for genotyping. Until 
today several isolates of HCV have been sequenced and distinct genotypes have been
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proposed on the basis of differences both in the coding and the non-coding regions of 
the virus (Simmonds., 1995; Okamoto and Mishiro., 1994; Brechot., 1993).
Until today the genomic sequences of different isolates of HCV are the only 
available data for genotyping. The entire genomes of the 16 HCV isolates have been 
sequenced (Okamoto, 1992a; Choo, 1991; Inchauspe, 1991, Okamoto, 1992b, Kato, 
1990; Takamizawa, 1991; Chen, 1992, Honda, 1992; Tanaka, 1992, Wang, 1993; 
Okamoto, 1994; Okamoto, 1991; Okamoto, 1992c; Sakamoto, 1992) and compared 
to each other (Okamoto and Mishiro., 1994). The organization of genetic elements is 
the same in these 16 full length sequences of HCV, however the length of each 
genetic element differs between genotypes. In particular, 5’ UTR, E2, NS5a and 
3’UTR are the regions where length differs significantly across genotypes. These 
variations for 16 different isolates are summarized below in Table 1.1.
Table 1.1: Genetic structure of the 16 HCV isolates with entirely sequenced genomes
Isolate Locatn, Tot.
# o f  
fits
ORF
aa
5 ’
UTR
nt
C
aa
E l
aa
E2
aa
FS2
aa
NS3
aa
NS4a
aa
4b
aa
NS5a
aa
5h
aa
2 ’
UTR
nts
HCV-l USA 9401 3011 341 191 192 426 197 651 54 261 448 591 27
HCV-H USA 9396 3011 341 191 192 426 197 651 54 261 448 591 22
HC-Jl Japan 9419 3011 341 191 192 426 197 651 54 261 448 591 45
HCV-J Japan 9400 3010 329 191 192 426 197 651 54 261 447 591 41
HCV-BK Japan 9404 3010 332 191 192 426 197 651 54 261 447 591 42
HCV-T Taiwan 9412 3010 341 191 192 426 197 651 54 261 447 591 41
HC-
J4/83
Japan 9412 3010 341 191 192 426 197 651 54 261 447 591 41
HC-
J4/91
Japan 9412 3010 341 191 192 426 197 651 54 261 447 591 41
HCV-
JKl
Japan 9395 3010 324 191 192 426 197 651 54 261 447 591 41
HCV-JT Japan 9412 3010 341 191 192 426 197 651 54 261 447 591 41
HCV-JT’ Japan 9411 3010 341 191 192 426 197 651 54 261 447 591 40
HC-C2 China 9411 3010 341 191 192 426 197 651 54 261 447 591 40
HC-G9 Indo-
nesai
9440 3011 341 191 192 426 197 651 54 261 448 591 66
HC-J6 Japan 9481 3033 340 191 192 430 197 651 54 261 466 591 42
HC-J8 Japan 9481 3033 341 191 192 430 197 651 54 261 466 591 41
NZLl New
Zealand
9425 3021 339 191 192 432 197 651 54 261 452 591 23
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A classification system was proposed due to the differences in the 5’UTR of 
the different HCV groups, and a phylogénie tree was constructed where HCV 
variants were classified into six equally divergent main groups of sequences, many of 
which contained more closely related groups within them. The main types have been 
numbered 1 to 6 and the subtypes have been lettered a, b, and c in order of discovery 
(Simmonds et al., 1993a and b). Sequences in the upstream 5’ UTR are far more 
conserved then the sequences in the open reading frame. Relatively few sequence 
differences exist between HCV genotypes, whereas sequences of different subtypes 
may be identical. However the 5’UTR sequences of genotypes 1 to 6 are distinct and 
several virus typing methods are currently used in the laboratories world wide. In 
practice, although existing genotypes can be recognized, it is problematic to assign 
new genotypes on the basis of sequence comparisons in this region alone. Therefore 
it seems essential that sequence comparison of putative new genotypes should be 
extended to the coding regions such as C, and NS5.
Some genotypes of HCV such as la, lb, 2a, and 2b, have been reported to 
show a broad world wide distribution whereas others such as 5a and 6a have only 
been found in specific geographical areas. Genotype lb seems to be the most 
common variant worldwide with a high incidence in Japan and Western Europe. The 
prototype la is relatively rare in these areas but the most common form in America. 
Type 4 is the principle form in the Middle East and Central Africa (Takada et al., 
1993; Dusheiko et al., 1994). Besides the geographical distribution in many European 
countries genotype distribution vary with age of the patients reflecting the rapid 
changes in genotype distribution with time within a particular geographic area.
Turkey is just in between the regions. Southern Europe and Middle East,
where genotypes lb and 4a, respectively, are particularly common. However, till to
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date no significant genotyping or subtyping studies have been reported for Turkey. 
The unconfirmed information was mentioned in a couple of articles stating the HCV 
lb subtype for Turkish population, but this statement needs to be confirmed by targe 
scale studies (Simmonds et al., 1995).
Once the rate of nucleotide sequence change of HCV is known it ought to be 
possible in principle to calculate the time of divergence between subtypes and types 
of HCV. Rates of sequence change over relatively short intervals of time are 
provided by a number of studies of HCV carriers or experimentally infected 
chimpanzees as mentioned before (Okamoto, 1992a) or between individuals after 
several years of transmission of HCV from one to the other, (Cuypers et al., 1991). 
Estimates of 0.144% (of the complete genome) and 0.192% (of the 5’ end 
nucleotide) changes per year have been reported (Ogata et al., 1991; Okamoto, 
1992a). Using the former figure and assuming a constant rate of divergence, it can be 
calculated that variant of the same genotype, for example HCV-BK and HCV-J that 
differ by 9%, diverged approximately 30 years ago, whereas subtypes (20% to 23% 
sequence difference) diverged 70-80 years ago. Finally, the divergence of the major 
genotypes can be predicted to have occurred 100 to 120 years ago. This reasoning 
would suggest that HCV is a relatively recent infection of humans, with relatively 
short evolutionary history with that of other human viruses. However such a simple 
reasoning might lead to a wrong estimation where there might be several other 
factors which might also effect the rate of divergence of the HCV genome and the 
divergence can date back to 1000 years.
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The fact that the majority of patients who acquire HCV progress to develop 
chronic infection suggests that even though HCV specific CTL activity is present, it 
is insufficient to eliminate HCV in most cases. Both host and viral factors may play a 
role in viral persistence. The genetic makeup of the patients may not allow for 
efficient processing and presentation of the HCV proteins to the immune system. The 
low level of HCV replication and hence attenuated antigenic display, or replication in 
a privileged reservoir may allow this virus to escape immune surveillance. HCV may 
also down-regulate the host immune response. The marked genetic heterogeneity 
may also allow HCV to escape the immune recognition through changes in its 
antigenic determinants.
Cytotoxic T lymphocytes (CTLs) are thought to be one of the major host
defense arms against viral infection and are also implicated in the
immunopathogenesis of viral infection. Cellular immune responses, particularly those
mediated by CD8*^  CTL may be important in the pathogenesis and control of HCV
infection. CTL have been found to offer protection in vivo against a number of viral
infections. In their attempt to control viral infection by eliminating the viral infected
cells, tissue damage occurs. Several lines of evidence suggest that the T cell arm of
the cellular immune response is activated in chronic HCV infection. First,
immunohistochemical studies in chronic HCV infection have demonstrated that the
intrahepatic inflammatory infiltrates consist mainly of CD8^ and CD4^ cells. The
majority of these intrahepatic lymphocytes are activated with up-regulated expression
of immune adhesion molecules. Second, circulating CD4^ lymphocytes that respond
to HCV proteins have been demonstrated in patients with chronic HCV infection and
their activation can also enhance the generation of in vitro HCV-specific CTL activity
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1.4 IMMUNOLOGY OF HEPATITIS C VIRUS INFECTION
in the liver and peripheral circulation has been identified in a number of patients, 
(Nelson et al,, 1997).
Recently the presence of CTLs that recognize endogenously synthesized HCV 
antigen in the peripheral blood of some patients with HCV infection by stimulation of 
peripheral blood lymphocytes (PBLs) with HCV synthetic peptides has been shown. 
The CTLs particularly recognized an epitope present in the core protein of the HCV 
between residues 88-96, which maps to a highly conserved region of the HCV 
genome among the isolates, (Hiroishi et al., 1997).
Attempts to explain the clinical expression and the behavior of chronic 
hepatitis C by viral factors have shown the importance of the viral genotypes and the 
level of viremia for the clinical presentation. However, there remain large 
inconsistencies, and it is very likely that the immune response of the host can modify 
disease outcome. Polymorphisms of the major histocompatibility complex (MHC) 
influence immune responses. For some viral infections a protective or predisposing 
effect of certain human leukocyte antigens (HLA) could be shown. At present there 
are very few data concerning hepatitis C. The HLA-DR5 antigen has been reported 
as a protective factor against a severe outcome of chronic infection, whereas DR3 
has been shown to prédispose to the expression of antinuclear antibodies and DR4 to 
be associated with concurrent immunological diseases in patients with hepatitis C. 
Also MHC class II allele DRB 1*0301 appears to predispose to progression to 
chronic active hepatitis C, whereas the class II alleles DRB 1*1301 and DQA1*0103 
appear to provide protection against chronic active infection with hepatitis C virus, 
(Hohler et al., 1997).
A major advance in understanding the regulation of specific immune
responses to infectious agents is the identification of two subpopulations of the helper
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T lymphocytes, termed T-helper type l(Thl) and Th2, based on cytokine secretion 
profiles, Thl cells promote cellular immunity and cytotoxic T-lymphocyte responses, 
and they produce predominantly interleukin (IL)-2, interferon gamma (IFN-y), and 
tumor necrosis factor p, Th2 cells favor development of humoral immunity and 
produce IL-4, IL-5, ILIO or IL-13. In human diseases and animal models, evidence 
has been generated that cellular immune responses promoted by the Thl-related 
cytokines are associated with resistance to infection while Th2-related cytokines 
exert negative immunoregulatory functions. An imbalance of Thl and Th2 cytokine 
production may be related to disease progression in infectious diseases and namely in 
HCV. It has been shown that the majority of CDA  ^ T-cell clones derived by 
phytohemagglutinin stimulation of single T cells from liver of chronic hepatitis C 
patients exhibit cytolytic activity and produce predominantly Thl-type cytokines. It 
has also been shown that there is a predominant Thl type of cytokine secretion by 
peripheral blood mononuclear cells (PBMC) responding to a nonstructural protein of 
HCV in chronic hepatitis C patients. HCV specific Th2 like clones are reported to 
compartmentalize in the diseased liver. The roles of these Th2 like cells in HCV 
pathogenesis and in the evolution from acute to chronic infection is not yet known. 
However it is suggested that as well as the hypervariable nature of the HCV genome 
the Th2 responses can also be involved in the progression to chronic disease. The 
Th2 like responses in acute HCV infection may down regulate the deleterious effects 
of Thl responses and may protect the hosts from lethal liver damage. In other words, 
it is a protective mechanism to minimize liver cell damage, but at the expense of the 
potential eradication of the virus and thereby chronic infection. Therefore it can be 
concluded that the Th2 like responses in HCV infection is a useful predictor of 
chronicity, (Tsai et al., 1997).
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Presently, the only therapeutic approach to HCV is long-term treatment with 
alpha interferon, alone or in combination with ribavirin (Main et al., 1995). This 
treatment is effective only for a minority of the patients, and the development of a 
more effective therapeutic agent and or of a prophylactic immunogen still remains an 
important public health issue. This is implicated in the increasing number of adult 
liver transplants (Alter et al., 1995).
Factors that have been frequently shown to influence response to influence 
response to interferon treatment include age and duration of infection, presence of 
cirrhosis before the treatment, genotype, and pretreatment level of circulating viral 
RNA in plasma. Response to IFN therapy differs among the six HCV genotypes, but 
is observed at some level in all HCV genotypes worldwide. Of the two predominant 
HCV genotypes, HCV-la and HCV-lb both exhibit a high level of resistance to IFN 
therapy. For genotypes 2a, 2b, and 3a increased rates of long term response to 
interferon treatment have been observed. In a comparative study it has been shown 
that long term normalization of alanine transaminase levels (more than 12 months) 
was infrequently achieved in those infected patients with the genotype 1 variants 
(29%) when compared with 52% of genotype 2 and 74% of genotype 3, (Peter 
Simmonds, 1995).
Recently others have sequenced clinical isolates of the HCV genome and 
correlated mutations within a discrete region of the NS 5 A protein, termed the IFN 
sensitivity determining region (ISDR), of the HCV-lb with the IFN sensitive 
phenotype. These studies demonstrated that the strains closely matching to the 
prototype HCV-lb, NS5A sequence correlated with complete IFN resistance 
(Enomoto et al., 1995, 1996).
1.5 TREATMENT OF HEPATITIS C VIRUS INFECTION
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In a more recent study a possible mechanism underlying this HCV resistance 
to IFN therapy has been proposed (Gale et al., 1997). The IFN-induced cellular 
antiviral response is mediated in part by the actions of the Mx proteins, the 2’-5’ 
oligoadenylate synthetase, RNAse L, and PKR. Induced by IFN, these antiviral 
effector proteins block viral gene expression in multiple levels. PKR protein kinase is 
the one which is most widely studied among these antiviral proteins. It is known that 
the PKR phosphorylâtes the a  subunit of the eukaryotic translation initiation factor 2 
(eIF-2a) resulting in a global cessation of protein synthesis and a concomitant block 
in viral replication within the infected cell. To counteract the deleterious effects of 
IFN induction and PKR activation, many viruses have evolved mechanisms to block 
the activity of the PKR with specific kinase inhibitory molecules; for example the Tat 
protein encoded by the HIV virus is a PKR kinase inhibitor. The large population of 
IFN resistant HCV indicated that this protein probably utilizes a similar mechanism . 
Although the function of NS5A and its role in viral replication had been unknown, it 
has been suggested that NS5A, by an ISDR-directed mechanism, may mediate IFN 
resistance by interacting with and repressing the IFN induced protein kinase PKR 
(Gale etal., 1997).
1.6 MOLECULAR BIOLOGY OF THE HEPATITIS C VIRUS
Hepatitis C virus (HCV) which is the major causative agent of non-A non-B 
hepatitis (NANBH) was first identified by the molecular cloning of the virus genome 
in 1989 (Choo et al, 1989). It is an enveloped, positive strand RNA virus with a 
genome size of around 9.5 kilobases (Kato et al. 1990, Chen et al 1992). By the 
analysis on sequence similarity and hydropaty profile, the genome of the HCV is
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shown to be related with that of flaviviruses and pestiviruses and therefore this vims 
is placed in a new monotypic genus in the flaviviridae family (Simmonds et al, 1995).
The single stranded RNA genome of the vims contains a large open reading
frame of 9,030 to 9,099 that codes for a large poly-protein of 3,010 to 3,033 amino
acids (Choo et al, 1991; Kato et al 1990; Takamizawa et al, 1991, Deleersnyder et al,
1997). This poly-protein product is shown to be processed by a combination of host
and viral proteinases to produce at least ten proteins post-translationally (Figure 1.2).
The proteins that are closer to the amino terminal of the poly-protein are termed as
stmctural and the rest closer to the carboxyl terminal are called non-stmctural (NS)
proteins (Houghton et al, 1991; L.J.V. Doom, 1994). As a result four domains are
evident including the two untranslated regions (UTRs) one at the 5’ and the other at
the 3’ of the genome (Han et al, 1991). The stmctural region includes four proteins;
the core protein (C), two putative envelope proteins, which are glycosylated, called
as El and E2 and a short protein called p7. These N-terminal proteins are thought to
be involved in the forming of the viral particle. The non stmctural region on the other
hand encodes for proteins NS2, NS3, NS4, and NS5. Some of these proteins are
shown to be cleaved into smaller units and are thought to be involved in the
replication of the vims'in the cell (Han et al, 1991; Brechot, 1993; Doom 1994). The
HCV gene order has been determined as 5’-C-El-E2-p7-NS2(p23)-NS3-NS4A-
NS4B-NS5A-NS5B-3’. Polyprotein cleavages in the stmctural region (C/El, E1/E2,
E2/p7, and p27/NS2) are catalyzed by a host signal peptidase localized in the
endoplasmic reticulum (ER), (Hijikata et al, 1993a; Lin et al, 1994). Cleavage at the
C/El, E1/E2 and NS2/NS3 sites are co-translational, whereas those at the E2/p7 and
p7/NS2 occur post-translationally and generate two precursors for E2; E2-NS2 and
E2-p7. (Deleersnyder et al, 1997). The nonstmctural proteins are processed by two
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virus protéinases, the NS2 (p23) and NS3 (Bartenschlager et al., 1993; Grakoui et 
al., 1993 a, b, and c; Fourmilier et al., 1996).
At present, little is known about the molecular mechanisms of the HCV 
replication, however it is thought that it resembles with the replication of the other 
positive-stranded RNA viruses; that is following the entry and uncoating in 
the cytoplasm of the host cell, the viral genome acts as a template for the synthesis of 
the complementary (minus) RNA molecule. The minus-strand than in turn serves as a 
template for the synthesis of the progeny positive-stranded RNA molecules. It has 
been impossible to detect any DNA intermediates in the serum or liver of the effected 
individuals, besides it has been shown that the region NS 5 encodes a protein (will be 
discussed in detail later) that has been demonstrated to have a RNA dependent RNA 
polymerase activity (Chung and Çaplan, 1992). Antigenomic (minus) RNA strands 
have been detected in the serum and in the liver of some patients (Takehara et al, 
1992; Fong et al 1991; Shindo et al, 1992), which indicates the presence of RNA 
intermediates in replication (Doom et al, 1994). As antigenomic strand synthesis 
should start at the 3’ terminus, some 6-8 basepairs repeating sequences that are found 
both at the 5’ and the 3’ UTRs may be involved in secondary stmcture formation or 
cyclisation of the RNA genome (Inchauspe et al., 1991).
Evidence that HCV does not replicate efficiently in cell culture systems has 
been a leitmotif in the HCV literature. All published reports indicates that the level of 
HCV propagation is extremely low in cultured cells, requiring the use of very 
sensitive detection methods such as reverse transcription-PCR (RT-PCR) to monitor 
infection and replication (Yoshikura et al., 1996). Nevertheless, reports of vims 
replication have been made using systems from hepatic tissue, (Ito et al., 1996) and 
peripheral blood mononuclear cells (PBMC), while in vitro infection systems have
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been reported from human T and B cell lines(Bertolini et al., 1993; Shimizu et al., 
1992). Very recently, (Baumert et al., 1998) showed that hepatitis C virus structural 
proteins assemble into virus-like particles in insect cells, which is one of the first 
evidences on the assembly of the virus.
1.6.1 Untranslated Regions of Hepatitis C Virus
1.6.1.1 5’ Untranslated Region (UTR)
The complete 5’ UTR comprises 341 nucleotides (Han et al, 1991; Chen et al, 
1992), but many shorter sequences have been detected and reported (Okamoto et al, 
1990; Choo et al, 1991; Kato et al 1990). This region is thought to be involved in the 
regulation of the translation and the replication of the genome. Studies made on 
ribonucléase sensitivity analysis and thermodynamic secondary structure modeling, 
(Brown et al, 1992; Tsukiyama-Kohara et al., 1992) have revealed the fact that a 
large conserved stem-loop structure is present in the proximal part of the 5’ UTR and 
might act as an internal ribosomal entry site (1RES), (Wang et al., 1993). HCV poly­
protein translation seems to be cap independent and initiate at the 1RES within the 5’- 
UTR proximal to the initiator AUG codon of the poly-protein. The translation 
initiation seems to be inhibited by the presence of a 27 nucleotides sequence that is 
capable of forming a stable hairpin structure (Han et al 1991).
1.6.1.2 3’ Untranslated Region (UTR)
Until very recent studies in the HCV area, the considerations about the 3’
terminal region of the genome was incorrect. A number of studies suggested that the
3 ’ terminus of the genome terminated in a poly(U) or a poly(A) tract. However more
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detailed analysis of the 5’ end of the negative anti-genomic RNA strand in the 
infected liver cells revealed the presence of a novel 98 nucleotide sequence 
downstream of the presumed genomic terminus, (Tanaka et al,, 1995; Kolykhalov et 
al., 1996; Berwyn Clarke, 1997). Detailed sequence analysis on the newly discovered 
3’ UTR sequence showed that it can be considered as a tripartite structure 
comprising the conventional 3’ end, a poly(U) tract and the new highly conserved 
sequence known as the 3’X tail. However, the poly(U) region appears to be 
extremely heterogeneous between different virus isolates and even within the same 
infected liver. In contrast, the 3 ’X tail sequence is highly conserved even between the 
two most genetically divergent HCV genotypes, lb and 2a, although it has been 
reported that the lb isolates also contain two additional uridine residues at the 
extreme 3’ terminus, (Tanaka et al., 1996, Yamada et al., 1996). Computer modeling 
of the 3’ terminus predicted that this region can fold into a stem loop structure , 
(Kolykhalov et al., 1996) suggestive of a critical functional component in virus 
replication as shown for many other positive stranded viruses.
1.6.2 Open Reading Frame of the Hepatitis C Virus
1.6.2.1 Structural Proteins of Hepatitis C Virus
1.6.2.1.1 Core Protein (C or p22)
The first structural protein is the HCV core protein (p22). Unlike the 
envelope proteins El and E2 it lacks potential N-glycosylation sites. Its N-terminal 
region is highly basic while the C terminus is hydrophobic. The amino acid sequence 
is well conserved among different HCV isolates (Bukh et al., 1994) which suggests
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the importance of this protein for the survival of the virus. Also because of this 
property, both recombinant core proteins and synthetic peptides, presenting linear 
core epitopes, can be used for efficient detection of antibodies in most patients sera 
(Doom et al., 1994). HCV core protein is a multifunctional protein. First it was 
shown that HCV core protein binds to cellular membranes, RNA molecules, and the 
60S ribosomal subunit, and the RNA and ribosome binding domains have been 
mapped to its N terminus. More recent data revealed that the core protein can form 
dimeric and multimeric complexes (Santolini et al., 1994). The ability of the protein 
to be multimerized and bind to RNA at the same time indicate that this protein plays 
an important role in the assembly of the HCV nucleocapsid. Besides this primary 
function of the core protein in the encapsulation of the virus, it also plays important 
roles in gene expression regulation. A lot of data have been accumulated indicating 
that HCV core protein is a trans-acting regulatory protein. The 22-kDa core protein 
trans-suppressed CAT gene expression under the control of various promoters (Ray 
et al, 1995; 1997; 1998). It was reported to regulate the replication and the 
expression of the HBV genome (Shih et al., 1993) and to trans activate c-myc 
oncogene (Ray et al., 1996a). It also enhanced the H-ras oncogene activity in 
immortalizing rat embryo fibroblast (Ray et al., 1996b). Hepatitis C vims core protein
is also shown to repress p21 WAFl/CIPl/SIDl promoter activity (Ray et al., 1998). A very
recent study (Matsumoto et al., 1997) showed that the HCV core protein interacts 
with the cytoplasmic tail of the Lymphotoxin-P receptor which is involved in the host 
defense system. This result implicates that HCV core protein is a potential modulator 
of the host immune system and it is involved in a mechanism for viral evasion of host 
defenses, perhaps allows for viral persistence.
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Having a wide variety of functions, the core protein has been shown to be 
accumulated both in the cytoplasm and the nucleus. It has been reported that during 
maturation, the core protein undergoes two consecutive membrane dependent 
cleavage events at amino acid residues 173 and 174 and 191 and 192. As a result two 
forms of the core protein, C173 (aas 1 to 173) and C191 (aas 1 to 191) are 
generated. Core protein products representing both C l73 and C191, produced from 
either an entire HCV polyprotein or various polyprotein precursors, display a 
cytoplasmic localization while the C l73 expressed in the absence of C l91 is able to 
translocate into the nucleus. These observations suggest that an indirect or direct 
interplay between these two forms of the core protein, generated by the preferential 
cleavages, may determine their subcellular localization (Santolini et al., 1994; 
Moradpour et al., 1996).
1.6.2.1.2 Envelope Proteins (El and E2)
The other two structural proteins El and E2 are putative vird envelope
proteins. Glycoprotein gp33 (El, also referred as gp35 in some references) contains
many potential N-glycosylation sites and glycosylation of this protein have been
demonstrated in a cell free glycosylation system. (Hijikata et al., 1991 a).
Transmembrane transport of the gp33 is presumably facilitated by a N-terminal
stretch of 20 hydrophobic amino acids that may function as a signal sequence,
recognized by cellular signalases, thereby cleaving the core protein p22 from the
precursor protein. Between residues 350-390 a stretch of hydrophobic amino acids is
present, which could act as a membrane anchor (Heinz et al., 1992).
As it was mentioned before, the processing of the capsid protein and the two
membrane associated glycoproteins El and E2 is mediated by host signalases
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(Grakoui et al., 1993a; Hijikata et al., 1991). Analysis of the location of the cleavage 
sites between stmctural proteins is based on determination of the N-terminal amino 
acid sequences of El and E2. The first amino acid residue of El has been identified 
as Tyrl92 and the first residue of E2 as His384 (Hijikata et al., 1991) or Glu384 (Lin 
et al., 1994) depending on the isolate. El and E2 are both preceded by hydrophobic 
segments (residues 174-191 and 371-383 of the polyprotein, respectively) that may 
be considered as signal sequences. The E2 protein seems to display a complex 
processing consistent with the generation of multiple E2 species (Lin et al., 1994; 
Mizushima et al., 1994) and forms a stable complex with El which is 
coimmunoprecipitable (Dubuisson et al., 1994; Grakoui et al., 1993a; Lanford et al., 
1993; Ralston et al., 1993)
Glycoprotein gp72 (also referred as gp70 in some references) is encoded by 
the E2/p7 and has a protein backbone of 38 kilodaltons (Bradley et al., 1992). A 
repeated amino acid sequence has been observed between residues 471-511; Pro- 
(X)s-Pro-(X)6- Pro-(X)6- Pro-(X)fi- Pro-(X)f,- Pro-(X)5-Pro (Kato et al., 1991). A 
cysteine residue is present in each of the last four intervening (X) sequences, and 
their positions seemed conserved. The HCV gp72 is more heavily N-glycosylated, 
and the full length gp72 is not secreted from the cell but remains membrane 
associated. Presumably this is caused by the presence of a single transmembrane 
anchor, since the studies showed that C terminal truncated E2/p7 protein is rapidly 
secreted.
Comparison of the available E2/p7 sequences revealed the presence of 
hypervariable regions (Hijikata et al., 1991 b; Kato et al., 1992 a, b) at the N-terminal 
of the E2 protein. One of these regions HVRl is located directly downstream of the 
putative cleavage site between El and E2/p7 (between residues 380 and 385) and
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covers the 30 N-terminal residues (384-414) of the E2/p7 protein (Weiner et al., 
1991 a, b). HVRl seems to lack a conserved secondary structure and resembles the 
V3 loop of the human immunodeficiency virus 1 gpl20 (Weiner et al., 1992). 
Specific antibody reactions were detected against peptides corresponding to linear 
epitopes in HVRl, indicating that the N-terminal part of the E2 region encodes 
antigenically distant variants, subjected to immune selection (Weiner et al., 1992, 
Lesniewski et al., 1993). The observed hypervariablity may result from sequential 
mutations leading to escape mutants (Kato et al., 1993a). Although HVRl shows 
hypervariation during most chronic infections, conservation has also been observed 
(Van Doom et al., 1994). This is presumably due to the absence of selective pressure 
favoring new mutants caused by an inadequate immune response against the initial 
HVRl epitope. The variability of the gp72 may have significant implications for the 
development of a protective immune response and is important for vaccine strategies.
Escape from the host immunosurveilance by means of mutations in HVRl
might be involved in the mechanism of persistent infection by HCV, which results in
chronic hepatitis and eventually hepatocellular carcinoma (Weiner et al 1992; Kato et
al., 1993). Viral isolate-restricted neutralizing antibodies against HCV have been
demonstrated recently in infected individuals (Farci et al., 1994; Shimizu et aJ., 1994)
but their molecular target is presently unknown. Several observations have suggested
that the HVRl could be involved in the neutralization of the HCV. This assumption
is based on the fact that HVRl is the most variable region on the HCV genome
(Weiner et al., 1991a; Hijikata et al., 1991), contains linear epitopes that are
recognized by the patients’ antibodies (Weiner et al., 1992) and mutates rapidly in
vivo (Kumar et al., 1993) suggesting that it is under the selective pressure of the host
immune system. This hypothesis is further substantiated by the lack of variability in
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the HVRl observed in an aganunaglobulinemic patient over a period of 2.5 years 
(Kumar et al., 1994). Recent data obtained in vitro suggest that antibodies, present in 
human sera and directed against the HVRl as well as against the E2 protein of HCV, 
can prevent the binding of HCV to cells (Zibert et al.,1995; Rosa et al., 1996). 
Another recent study carried out in order to show whether the HVRl of the E2 
protein is a critical neutralizing domain (Farci et al., 1996). Prevention of HCV 
infection in chimpanzees by hyperimmune serum against the hypervariable region 1 
has been detected.
The C terminal position of the E2 protein is not absolutely clear at present. 
The location of E2 in the HCV open reading frame was predicted to be from amino 
acids 384 to 729 (Takamizawa et al., 1991). It was reported that in an in vitro 
translation system, the full E2 coding region does not extend past amino acid 740 
(Hijikata, 1991). A more recent data suggested that the N terminal position of NS2 
lies at about amino acid 810 although the precise C-terminal position of E2 is not 
known (Matsuura et al, 1994). Therefore the residues that, the other structural 
protein p7 is within, could not been detected and it might be possible that it might be 
expressed with or without E2.
Viral envelope proteins play role in several aspects of the viral life cycle such 
as receptor binding, penetration of host cells, and virus morphogenesis at budding. 
Expression studies using recombinant HCV cDNA templates have demonstrated 
hetero-oligomer formation between the El and the E2 proteins detected by 
immunological means (Grakoui et al 1993; Lanford et al., 1993; Ralston et al 1993; 
Dubuisson et al., 1994; Matsuura et al., 1994; Selby et al., 1994). A recent study 
have been reported E1-E2 binding by far-Westem blotting and pull-down assay 
mainly using bacterial-expressed recombinant proteins. The major contribution to the
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El-binding of E2 was mapped within the region in the vicinity of HVR2, and the 
“WHY” sequence within the region played a crucial role in the E1-E2 association. 
Neither HVRl nor HVR2 of E2 were necessary for interaction. By using similar 
systems it was also demonstrated that the E2-binding of E 1 is mapped to the N- 
terminal part of El. (MinKyung et al., 1997).
El and E2 are candidate antigens for future vaccines to hepatitis C, as the 
NS 1 protein of flaviviruses are E2 protein of pestiviruses, the counter parts of the E2 
protein, have been reported to produce neutralizing antibodies (Brandriss et al., 1990; 
Roehrig et al., 1990; Weinland et al., 1992; Rumenapf et al., 1993). In a study anti- 
E2 antibodies were detected in most of the chronic NANBH patients (93%). The 
anti-E2 antibodies present in patients’ sera reacted well to native E2. These anti E2 
antibody may be diagnostically useful (Harada et al., 1995).
As mentioned previously, before the cellular proteases, such as cellular 
peptidase are involved in sequential co-translational processing of the cleavage sites 
on the N-terminus of El, E2 and possibly NS2. The NS2-NS3 cleavage is mediated 
in cis by a zinc requiring metalloproteinase encoded by the NS2 itself The region 
between residues 898-1233 was shown to be essential for the detection of the second 
viral protease (Hijikata et al 1993a). NS3 acts in cis on its own C-terminus but the 
remaining three C-terminal sites can only be processed by NS3 in trans (Tomei et al., 
1993). There is also homology between NS3 and nucleoside triphosphate-binding 
helicase enzymes that are presumably involved in the unwinding of the binding ds 
RNA replicative intermediate necessary for genome replication (Houghton et al., 
1991).
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1.6.2.2 Nonstructural Proteins
1.6.2.2.1 Nonstructural Protein 2 (NS2)
The NS2 protein is the first nonstructural protein of the hepatitis C virus 
genome. It has been shown to be a transmembrane protein with its carboxyl terminus 
translocated into the lumen of the ER while its amino terminus lies in the cytosol, 
(Santoloni et al., 1995). Although immunoprécipitation studies have shown that NS2 
is closely associated with the structural proteins, the biological function of the 
majority of the NS2 protein is still unclear. However, detailed study of the proteolytic 
processing of this region of the polyprotein has revealed an unexpected proteolytic 
function of this protein, particularly mapped to its carboxyl terminus, (Clarke, B., 
1997).
Based on the analogy with the genus Flavivirus it would be assumed that the 
NS3 serine protease was responsible for cleavage at the NS2/NS3 junction in HCV. 
However mutation at the active site Ser-1165 in NS3 , although abolishing the 
processing of the downstream sites, it did not affect proteolytic cleavage at NS2/NS3 
junction. The fist report of the existence of a second virus-encoded protease was 
made by Hijikata et al., (1993a) who showed that the protease responsible for 
cleavage at this position comprised elements of both the NS2 and NS3 proteins. 
Further mapping studies, (Hijikata et al., 1993a, Grakoui et al., 1993b) revealed the 
proteolytic domain responsible for this activity to amino acids 827-1207. This region 
encompasses the carboxyl terminus of NS2 and the amino terminus of NS3 and, 
therefore, overlaps the active domain of the serine protease. Apart fi’om internal 
autocatalytic cleavage of itself, no other proteolytic processing functions have been 
mapped to this enzyme. It has no known homology to other classes of proteases but
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has been proposed to be a metalloprotease since its activity can be inhibited by EDTA 
and stimulated by zinc (Zn '^') ions. Mutational analysis of the region surrounding the 
cleavage site (Hirowatari et al., 1993; Reed et al., 1995) has shown that the NS2/3 
protease is remarkably tolerant to amino acid mutations, apart from substitutions 
such as proline which markedly affect the confirmation of the substrate.
Attempts on identifying the regions for enzymatic activity showed that the 
residues His-952 and Cys-993 in NS2 are involved. Nevertheless, some studies have 
shown that lack of NS2/3 protease activity even with wild-type residues at these 
positions (D’Souza et al., 1994), indicating a critical role for other residues. Despite 
the fact that the mechanism of action of the NS2/3 protease during virus replication is 
an autocatalytic czls-cleavage process, Grakoui et al. (1993b), observed using 
cotransfection experiments, that the NS2/3 junction could also be processed in trans.
1.6.2.2.2 Nonstructural Protein 3 (NS3)
The HCV nonstructural 3 protein (NS3) is a 70 kilodalton multifunctional 
enzyme with three known catalytic activities segregated in two somewhat 
independent domains. The essential machinery of a serine protease is localized in the 
N-terminal one third of the protein and nucleoside triphosphatase (NTPase) and 
helicase activities reside in the remaining C-terminal region. There is no evidence to 
suggest that the two domains of NS3 are separated by proteolytic processing in vivo.
The NS3 shows limited amino acid homology with corresponding flavi- and 
pestivirus proteins (Miller and Purcell, 1990). The N terminal one-third of NS3 
resembles a chymotrypsin-like serine protease, similar to that found in flaviviruses 
(Chambers et al., 1990) and pestiviruses. If the Ser-1165 in the proposed catalytic 
site is replaced with another amino acid, the proteolytic activity of the p72 is
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abolished (Tomei et al., 1993; Eckart et al., 1993). This protease is responsible for 
some processing steps of the precursor polyprotein into the mature proteins. All four 
cleavages that occur C terminally of the protease domain (NS3-NS4A, NS4A- 
NS4B, NS4B-NS5A, and NS5A-NS5B). These cleavage sites show several common 
features, which probably determine the substrate specificity of the NS3 protease 
(Grakoui et al., 1993a).
The His-57, Asp-81, and Ser-139 residues of the NS3 protease are conserved 
among all sequenced HCV strains and have been proposed to constitute characteristic 
serine protease catalytic triad, as in the NS3 protein of flaviviruses and pestiviruses. 
These three residues are essential for HCV NS3 proteinase activity as it has been 
showed by site-directed mutagenesis experiments (Hijikata et al., 1993). Recently it 
was shown that NS3 protease requires another virus-encoded protein NS4A, to 
cleave efficiently the nonstructural proteins (Bartenslager et al., 1993; Failla et al., 
1994; Lin et al., 1994, Tanji et al., 1995a). In addition to this requirement for a 
protein co-factor, there were reports of NS3 protease sensitivity to divalent metal 
ions, behavior that is not expected for a chymotrypsin-like serine protease. A recent 
report showed that the NS3 proteinase domain of the HCV is a zinc containing 
enzyme (Stempniak et 'al., 1997). Analysis of the metal content of the purified NS3 
protease domain indicated the presence of a single zinc atom per molecule of enzyme 
which in turn, implied the existence of a metal binding site. This study and the crystal 
structure of the NS3 protease domain shows that the role of the zinc atom is 
structural rather than cataljtical. The zinc atom is coordinated by Cys-97, Cys-99, 
and Cys-145 and the fourth ligand is a water molecule which is attached to the His- 
149 (Love et al., 1996; Stempniak et al., 1997).
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The C terminal two-thirds of NS3 also seems to constitute a somewhat 
independent domain. It contains conserved sequence motifs characteristic of the 
NTP-binding proteins and the so-called D-E-A-D superfamily of RNA helicases and 
several studies have demonstrated RNA-dependent NTPase and helicase activities 
with various recombinant forms of NS3. The NTPase activity has been characterized 
for a ~50 kilodalton N terminal NS3 containing only the helicase and for full-length 
NS3 (Hong et al., 1996). Similarly, the helicase activity has been characterized by 
using a truncated helicase domain (Kim et al., 1995) and a full-length NS3 complexed 
with NS4A (Hong et al., 1996). Despite the evidence that the both domains of NS3 
are active in the absence of one another in vitro, there is no evidence that they are 
separated by proteolytic processing in vivo. This may reflect economical packaging of 
essential viral replicative components, but it could also mean that there is a functional 
interdependence between the two domains. A recent report presents new evidence on 
interdomain communications that may indeed help to modulate the various NS3 
catalytic activities (Morgenstem et al., 1997). A contiguous NS3-NS4A protein 
precursor was expressed in transiently transfected COS cells and appeared to 
autoprocess intracellularly to a noncovalent NS3-NS4A complex. The complex was 
purified, and the serine protease, RNA-stimulated NTPase, and RNA helicase 
activities were characterized. The binding of poly nucleotides to the NS3 helicase 
domain not only stimulated the NS3-NS4A NTPase activity but also modulated the 
helicase and protease activities and thus showed the interconnectance of the two 
functional domains which seem to have independent mode of interaction 
(Morgenstem et al., 1997). The multiple functions of this protein suggests that it is 
exclusively utilized in the replication of the vims so it can be regarded as a promising 
target for the development of anti-HCV dmgs.
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Some evidence has been reported about the interference by the viral proteins 
on the intracellular signaling pathways. An inspection of the amino acid sequence of 
the HCV gene product revealed and arginine-rich domain located in the NS3 region 
(residues 1487-1500 of the polyprotein (Borowski et al., 1996, Takamizawa et al., 
1991). This sequence strongly resembles the inhibitory sequence of protein kinase 
inhibitor, responsible for the inactivation of the c-AMP dependent protein kinase A 
(PKA) that plays a crucial role in intracellular signaling, and the consensus sequence 
surrounding the phosphoacceptor amino acid in the substrates of PKA. Because of 
these similarities a synthetic peptide corresponding to this HCV sequence and a 
bacterially expressed 43.5 kilodaltons fragment of NS3 consisting of HCV 
polyprotein residues 1189 to 1525 potently inhibited PKA activity in vitro (Borowski 
et al., 1996). This observation indicates that NS3 or its fragment may act by 
inhibiting PKA in a c-AMP-independent manner, thereby interfering with the signal 
transduction of infected cell. In a recent study it was demonstrated that the formation 
of an in vitro complex between the NS3 fragment and the catalytic subunit of the 
PKA and the significance of the interactions observed for living cells was investigated 
and interference of the NS3 fragment with the PKA signaling has been demonstrated 
(Borowski et al., 1997).
Apoptosis in virus infected cells, either mediated by a viral protein(s) or by 
CTL recognizing the viral antigens, has currently been considered as a mechanism of 
clearance of the virus from the host (reviewed in ; Ravzi, 1995). Suppression of 
apoptosis on the other hand, is accordingly thought to be a major mechanism of viral 
persistence in the effected cell, which might be a crucial step toward malignant 
transformation in the case of infection with tumor viruses. These events raised the 
possibility that an HCV protein(s) has anti apoptosis activity to establish persistent
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infection which might be an important step toward development of hepatocellular 
carcinoma. It has recently been observed that NS3 suppresses actinomycine D- 
induced apoptosis probably through the decreased expression of p53. Interaction of 
the NS3 with the tumor suppressor p53, which probably abolishes its functions in 
DNA damage induced apoptosis of the liver cells, has been demonstrated recently by 
the observation that the NS3 protein of the HCV changes its localization from 
cytoplasm to nucleus in a tumor suppressor gene p53 induced manner (Ishido et al, 
1997). It is still unknown whether the transport of the NS3 to nucleus is mediated by 
the tumor suppressor gene p53 in a direct or indirect manner however the NS3 
protein is probably carried to the nucleus by p53 or a p53 induced carrier protein and 
thereby might interfere with the p53s functions in gene expression.
1.6.2.2.3 Nonstructural Protein 4 (NS4)
The nonstructural 4 protein is cleaved into two by trans acting NS3 serine 
protease. The NS4A is a 54 residue protein expressed immediately downstream of 
NS3 in the viral polyprotein, and a central stretch of hydrophobic residues in NS4A 
form an integral structural component of the NS3 serine protease domain. Previous 
cell transfection studies suggest that the NS3 serine protease domain cleaves the 
NS3-NS4A junction in cis, thus producing a mature non-covalent NS3-NS4A 
complex. The binding of NS4A appears to stabilize the NS3 protein and enhance its 
ability to trans process the NS4A-NS4B, NS4B-NS5A, and NS5A-NS5B 
(Bartenschlager et al., 1993; Eckart et al., 1993; Grakoui et al., 1993, Lin et al., 
1994). The minimal region of NS4A needed to stimulate the activity of NS3 was 
originally mapped to a central stretch of about 13 residues (Lin et al., 1995). These
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findings derived a physical explanation when the first X ray crystal structure appeared 
for an NS3 protease domain complexed with a synthetic NS4A peptide that spans 
essential NS3-binding residues (Kim et al., 1996). The structure shows that the 
peptide forms a ß-strand, intercalating within a ß-sheet of the NS3 protease. Thus, 
NS4A contributes an integral part of the NS3 protease domain and hence, the NS3 
protein (Morgenstern et al., 1997).
1.6.2.2.4 Nonstructural Protein 5 (NS5)
The nonstructural protein 5 is processed into NS5A and NS5B. Recent 
studies with a purified NS3 protease domain identified a potential fifth cleavage site, 
within the NS5A protein. Conserved sequence characteristics preceding the newly 
identified site show similarity to the prototypical NS3 serine protease cis recognition 
sequence. However further studies needed to infer whether the site is cleaved during 
viral replication in vivo (Morgenstem et al., 1997).
Two proteins a faster migrating form of 56 kilodaltons protein, p56 and a 
slower migrating form 58 kilodaltons of protein, p58 are produced from the NS5A 
region (Hijikata et al. 1993a; Kaneko et al., 1994; Tanji et al., 1994, 1995a) and both 
are phosho proteins. Recent findings indicate that both proteins are phosphorylated at 
the serine residues in the C-terminal region of the NS5A and the that p58 is 
additionally phosphorylated at serine residues in the central region, amino acid 
residues 2194 to 2204 (Tanji et al., 1995b). When only the NS5A region of the HCV 
genome is expressed in the cultured cells, most of the product is p56 and a trace 
amount is p58. In the presence of the NS4A however the production of the p58 is 
augmented strongly and both forms of NS5A are produced. In a recent study (Asabe 
et al., 1997) a N-terminal region of the NS5A protein is shown to have an important
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role in the phosphorylation of the central region of NS5A. When that region was 
deleted, phosphorylation of the central region of NS5A was no longer augmented by 
the NS4A protein. Also it has been demonstrated for the first time that the NS4A and 
NS 5 A are associated with each other, however the physiological role of the 
phosphorylation of the NS5A and its association with the NS4A protein is still 
remains to be clarified (Asabe et al., 1997).
The NS5B shows significant amino acid sequence homology with the putative 
RNA-dependent-RNA replicase from carnation mottle virus (CAEIMV, Miller and 
Purcell, 1990). The NS5B region contains a Gly-iAsp-Asp sequence (residue 2737- 
2739), which characteristic sequence motif for RNA-dependent-RNA polymerases of 
positive-strand RNA viruses. Therefore NS5B encodes the viral replicase and the 
activity of this enzyme has been demonstrated in vitro (Chung and Kaplan, 1992). In 
a recent study by using the baculovirus expression system the functional and 
biochemical characterization of the NS5B protein was made and in a cell free system 
the RNA-dependent RNA polymerase activity of the NS5B has been demonstrated 
(Behrens et al., 1996) which is in agreement with the sequence analysis made before. 
Also in this study it was shown that the NS5B mediated polymerization reaction is 
not to be limited to input RNAs containing the 3’UTR of HCV. RNA synthesis was 
also observed with unrelated input RNAs. This point strongly suggests that the NS5B 
protein is necessary but not sufficient for the replication of the HCV genome. Other 
viral or cellular proteins are needed to be involved in this process to restrict the RNA 
synthesis solely to viral templates.
The NS5B is primarily localized at the perinuclear region, suggestive by its 
association with the nuclear membrane and the endoplasmic reticulum or Golgi 
complex (Hwang et al., 1997). It is interesting because these findings suggest that the
n
HCV replication might take place in the membrane complex which is consistent with 
the findings on other RNA viruses as their RNA synthesis is shown to take place in a 
membrane complex.
It has been suggested (Okamoto et al., 1992b) that in some isolates a 
secondary structure of the genomic RNA exists at the C terminal part of the NS4 
region that could possibly form an IRES. This IRES would be located just upstream 
of a common in frame ATG codon allowing earlier and increased production of NS5- 
encoded replicase. Consequently, this would accelerate the replication rate of the 
genomic RNA.
2. MATERIALS AND METHODS
2.1 MATERIALS
2.1.1 Chemicals and Enzymes
All enzymes or reagents were purchased from the sources listed below:
Restriction enzymes
T4 Ligase and Buffer
Ribonucléase A
Tii^-Polymerase
Cloned Pfu DNA Polymerase
dNTPs
IPTG
Gel Extraction Kit 
Plasmid Purification Kit 
DNA Markers 
100 bp marker 
Ikb ladder
X EcoKlJHiruRll marker 
Protein Markers 
cDNA Synthesis Kit
ECL Western Blotting Detection Reagents
Transfer Membranes
Secondary Antibodies (Anti-Human)
Horse Radish Peroxidase 
Alkaline Phosphatase
MBI Fermentas 
MBI Fermentas 
Sigma
MBI Fermentas
Stratagene
MBI Fermentas
Boehringer Mannheím
Qiagen
Qiagen
MBI Fermentas
Pharmacia or Sigma 
Stratagene 
Amersham 
Sigma
Dako
Sigma
The Ni-NTA resin for histidine tagged protein purification was purchased 
from Qiagen. All other chemicals were purchased from Sigma, Difco or Carlo-Erba. 
All oligodeoxynucleotides were synthesized on a Oligo lOOOM DNA Synthesizer 
(Beckman) in the Molecular Biology and Genetics Department, Bilkent University.
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2.1.2 Equipment
The list of equipment used and their manufacturers are given below
Automatic Pipettes 
PIO 
P20 
P200 
PI 000
Filter and 3MiVl paper
Programmable dri-block temperature cycler
GeneAmp PCR System 9600
Heating Blocks
Centrifuges
Bioflige (pico)
Avanti J-25 I 
GS-15R 
Gel Tanks 
Horizontal 
Minicell 
Midicell 
Vertical 
Minicell 
pH meter
Spectrophotometer DU 640 
Power Supply РАС 300,
Slab Gel Drier (SGD 2000)
X-Ray Film 
UV Transilluminator 
Transferblot SD
Gilson
Eppendorf
Whatman 
Perkin Elmer
Stuarts Scientific
Heraus Instruments
Beckman
Beckman
E-C Apparatus Corporation 
Stratatgene
E-C Apparatus Corporation
Beckman
Beckman
BioRad
Savant
Kodak or Fuji
Herolab
BioRad
2.1.3 Plastic Disposables
The list of plastic disposables used and their manufacturers are given below;
Microcentrifuge Tubes Costar
0.2|il 
1.5p,l 
2,0pl 
Petri Dishes 
Syringes 
Test Tubes 
15ml 
50ml
Tips
Blue,
LP, Italy 
Fefarma
Costar and Nunc
Costar and USA/Scientific Plastics
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Yellow,
Crystal
ELISA Plates (96 well) 
Maxisorb 
Polysorb
Nunc
2.1.4 Bacterial Strains
Bacterial strains used in this study were E.coli M l5 and JM109. The 
characteristics of the two strains are summarized below.
Table 2.1: List of the E.coli strains used during the course of this study
Strain Genotype Usage Source
MI5(pREP4) F, Nal^ , Str^ , rif^ , lac, ara', 
gal', mtr, recA^ , uvr^ .
Production of 
recombinant 
proteins with pQE 
vectors
Villarejo and Zabin, 
1974
JM109 F, trame lacV^^{lacZ)m\5 
proAB/reckl endf l^ gyrMG 
(Naf) thi hsdR.\l (г'кш'к) 
suplBAA е14"(тсгА ) 
relK 1 A{lac-proP )^
Propagation and 
storage of the pQE 
vectors
Stratagene
Any E.coli strain that contains the pREP4 repressor plasmid, which carries 
the la d  gene whose product represses the transcription of the pQE promoter, can be 
used for the production of recombinant proteins. Here Ml 5 was used as it allowed 
high levels of expression and was easy to handle. JM109 on the other hand has a 
mutated lad  promoter which transcribes 10 fold more lac repressor therefore tightly 
represses the protein expression during the propagation and storage steps.
2.1.5 Growth and Storage of Bacterial Strains
All strains were grown in liquid culture in Luria-Bertoni (LB) medium (1% 
tryptone, 0.5% yeast extract, 1% NaCl) and on LA medium (1% tryptone, 0.5%
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yeast extract, 1% NaCl, 1.5% agar) supplemented with appropriate antibiotics. 
Antibiotics, ampicilin and kanamycin were used in this study.
Table 2.2: List of antibiotics used during the course of this study
Name Storage
Temperature
Stock
Concentration
Working
Concentration
Ampicilin -20°C lOOmg/ml 100|ig/ml
Kanamycin -20°C 30mg/ml 30p.g/ml
Strains of E.coli were stored in glycerol (long term storage). Glycerol 
cultures of E.coli were prepared by adding 0.81 ml of a fresh culture to 0.19 ml of 
sterile 80% glycerol in a sterile 1.5 ml microcentrifuge tube. The tubes were vortexed 
until homogeneity and were then flash frozen and stored at -70 °C until required. 
Bacteria were recovered by scraping the surface of the frozen glycerol with a sterile 
loop and streaking onto a LB-agar plate or by thawing and inoculating enough 
amount to the liquid LB broth. The plates or liquid media were incubated at 37 °C 
overnight.
2.1.6 Plasmids
pQE30 which is one of the pQE expression vectors was used for cloning and 
expression in this study. The pQE expression vectors provide high-level expression in 
E.coli of proteins or peptides containing 6xHis affinity tag. The tag may be placed at 
the N terminus; at the C terminus or at the C terminus of a protein utilizing its 
original ATG start codon. If small peptides are to be synthesized, they can be fused 
to mouse DHFR, where the poorly immunogenic DHFR stabilizes the peptide during 
expression and enhances antigenicity.
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The pQE plasmids belong to the pDS family of plasmids (Bujard et al., 1987) 
and were derived from plasmids pDS56/RBII and pDS78I/RBSII-DHFRS (Stuber et 
al., 1990). They contain the following elements.
• An optimized, regulable promoter operator element, consisting of the E.coli phage 
T5 promoter and two lac operator sequences.
• A synthetic ribosome binding site, RBSII, designed for optimal mRNA recognition 
and binding.
• Optimized 6xHis affinity tag coding sequence.
• The mouse DHFR coding sequence (in Typell vectors only).
• A multi-cloning site.
• Translation stop codons in all three reading frames.
• The transcriptional terminator %’ from phage lambda.
• The replication region and the gene for ß lactamase of plasmid pBR322.
The plasmid generated during the course of this study will be mentioned in the 
relevant chapter.
2.2 METHODS
2.2.1 RNA Isolation and cDNA synthesis
Total RNA was extracted from patient’s sera by the single step guanidinium 
thiocyanate method (Ausbel et al., 1991) with slight modifications (Wilson et al., 
1995).
600 |il serum was added to 3 ml denaturing solution (4M-guanidinium 
thiocyanate, 25 mM-sodium citrate, pH 7.0, 0. lM-2-mercaptoethanol and 0.5% jV- 
laurylsarcosine) and vortexed briefly. 300|il of 2M-sodium acetate pH 4.0, 3 ml water
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saturated phenol, and 600|j.l 49:1 chloroform:isoamyl alcohol were added 
respectively and mixed well by vortexing. This extract was then incubated on ice for 
15 minutes before centrifuging at 12,000 rpm for 15 minutes at 4 °C. The aqueous 
supernatant was precipitated with 1 volume of 100% isopropanol at -20 °C for 30 
minutes before centrifuging at 14,000 rpm for 20 minutes at 4 °C . The pellet was 
dissolved in 250pl denaturing solution and precipitated with 250|il 100% isopropanol 
incubated at -20 °C for 30 minutes before centrifuging at 14,000 rpm for 20 minutes 
at 4 °C. The pellet was then washed with 500 p.1 75% ethanol, centrifuged, air dried 
and resuspended in 10 p,l diethylpyrocarbonate-treated distilled water.
After incubation at 70°C for 5 minutes, the entire 10|il RNA is reverse 
transcribed, by the Stratagene RT-PCR kit, using random primers according to the 
producers instructions.
2.2.2 DNA Isolation
2.2.2.1 Small Scale Preparation of Plasmid DNA (Mini-Preparation)
This method is based on the alkaline lysis method of the method of Bimboim 
and Doly(1979).
The transformed bacterial strain containing the plasmid of interest was grown 
at 37 °C overnight in 3-5 ml of LB medium with the appropriate antibiotic. 1.5 ml of 
the bacterial culture was pelleted by centrifugation at 13,000 rpm for 1 minute at 
bench-top microflige. After discarding the supernatant, the cells were resuspended in 
0.1 ml of ice cold solution I and stored for 5 minutes on ice, then 0.2 ml of freshly 
prepared solution II was added to the tube. The tube was then gently mixed by
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inverting the tube several times and stored for 3-5 minutes at room temperature. 
Bacterial chromosomal DNA and proteins were precipitated by the addition of 0.5 
ml of ice cold solution III. The mixture was left on ice for 5 minutes, then centrifuged 
at 13,000 rpm for 5 minute at bench-top microfuge to pellet the host DNA and 
proteins. The plasmid DNA was then precipitated by adding 1.5 volume of ice cold 
absolute ethanol and incubating at -20 °C for 30 minutes. The tube was then 
centrifuged at 13,000 rpm for 20 minutes. The supernatant was discarded and the 
pellet was left for 15-20 minutes at room temperature to dry and then resuspended in 
20-30 }il of deionized, distilled water containing 10 ¡ig/ml RNase A. Samples were 
stored on ice for a few hours for RNase to work then kept in -20 °C for long term 
storage.
2.2.2.2 Medium Scale Isolation (Midi-Preparation)
Cells were grown in 50-100 ml of LB (containing appropriate antibiotic) 
overnight to saturation and plasmid DNA was isolated by using QIAfilter plasmid 
midi kit (Qiagen inc ), according to the manufacturers instructions.
2.2.3 DNA Elution From Agarose Gel
The desired DNA bands were cut from the agarose gel under UV light and 
DNA was extracted from agarose gel slices by QIAquick gel extraction kit (Qiagen 
inc.), according to the manufacturers instructions.
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2.2.4 Quantification Of DNA
2.2.4.1 Spectrophotometric Determination
The amount of DNA in samples were determined by reading the absorbance 
of samples at 260 nm. An OD260 of 1 corresponds to a concentration of 50 |ig/ml for 
double stranded DNA, 40 p.g/ml for single stranded DNA and 20 pg/ml for 
oligonucleotides (Maniatis et al., 1982)
2.2.4.2. Ethidium Bromide Fluorescence Quantification
DNA samples were loaded onto 1% agarose gel containing 0.5 pg/ml of 
ethidium bromide alongside standard DNA samples with known concentrations. After 
running the gel long enough to separate the bands, the approximate amount of DNA 
was quantified by visual comparison of unknowns with the known standards.
2.2.5 Recombinant DNA Manipulation Techniques
2.2.5.1 DNA Precipitation
Nucleic acids were concentrated by ethanol precipitation. To the estimated 
volumes of DNA solution, 1/10* volume of potassium acetate solution pH 4.8 ( 3 M 
with respect to potassium and 5 M with respect to acetate) and 2.5 volumes of ice 
cold ethanol were added. The solution was then incubated at -70 °C for 10-20 
minutes. Following the centrifugation for 10 minutes at 12,000 rpm in a 
microcentrifuge, the supernatant was removed and the pellet was washed with 70% 
ethanol, dried under vacuum for 5 minutes and finally resuspended in an appropriate 
volume of deionized distilled water (ddH20) or IxTE buffer pH 8.0.
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2.2.5.2 Restriction Enzyme Digestion of DNA
Restriction enzyme digests of DNA were carried out in a total volume of 20 
|il with 5-10 units of restriction enzyme. 1 |ul of boiled RNase A (1 mg/ml) was used 
where appropriate. The volume of enzyme was never greater than 1/10"’ of the 
reaction volume to prevent star activity of enzymes due to high glycerol 
concentrations. Buffers were used for each digest as recommended by manufacturer. 
Digestion reactions were incubated for 2-20 hours at 37 °C unless otherwise 
recommended.
2.2.5.3 DNA Ligation
DNA fragments were ligated into plasmid vectors as described in Maniatis et 
al., (1982). Ligations were performed in 10 p.1 reaction volumes containing 0.5 pg of 
plasmid DNA and molar excess of insert in the presence of 1-4 Weiss units of T4 
ligase and standard ligation buffer supplied with the enzyme (50 mM Tris-HCl pH 
7.4, 10 mM MgCb, 1 mM dithiothreitol, 1 mM ATP, 100 pg/ml bovine serum 
albumin) at either room temperature for 2-4 hours or at 16 °C for 4-16 hours.
2.2.5.1 Polymerase Chain Reaction
Double stranded DNA sequences were amplified by the polymerase chain 
reaction (Saiki et. al., 1988). Taq DNA polymerase was used to catalyze the reaction 
and the buffer conditions were as described by the supplier (MBI Fermentas). 
Buffered dNTPs (MBI Fermentas) were stored as a mixture of all four in a 10 mM 
stock and was used at a final concentration of 0.2 mM. The following reagents were 
mixed in a 0.2ml microcentrifiige tube;
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5 |j,l 1 Ox Taq Polymerase Buffer 
1 |il dNTP mix 
10 ng Template DNA 
1 |il Primer 1 (from 50 pmol/pl stock)
1 p,l Primer 2(from 50 pmol/p.1 stock)
Made up to 50 ¡il with deionized distilled water
The mixture was briefly vortexed and spun down before it was placed to the 
thermal cycler. After a 5 minutes denaturing step at 94 °C, 0.5 jj.1 (around 2 units of 
enzyme) of Taq Polymerase (MBI Fermentas) was added and the contents of the tube 
was carefully mixed and the tube was again placed into the thermal cycler and the 
pre-designed program was commenced. When the reaction was complete, amplified 
DNA was purified by agarose gel electrophoresis and gel extraction.
2.2.6 Transformation Of E.coli
2.2.6.1 Preparation of Competent Cells
Cells were made competent using a modification of the CaCl2 method 
described by Maniatis et al., (1982).
5 ml of LB was inoculated using a single colony from a freshly grown plate or 
200 pi saturated liquid culture of the E.coli strain to be used, and was incubated for 
approximately 2 hours at 37 °C, until the culture was slightly turbid ( ODeoo around 
0.6). The culture was cooled on ice for 5 minutes, 1.5 ml of aliquots were added to 
microcentrifuge tubes and pelleted by centrifuging at 13,000 rpm for 2 minutes. The 
cells were then resuspended in 500 pi of ice cold 50 mM CaCb by gentle pipeting, 
before being placed on ice for 30 minutes. The cells were spun down as before, the 
supernatant was removed, and the pellet was resuspended in 100 pi ice cold 50 mM 
CaCb by gentle pipeting. The cells were then stored on ice for at least 30 minutes
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before the addition of the DNA. Alternatively competent cells were prepared and 
stored at -70 °C until required. 500 ml of LB was seeded with a 10ml overnight 
culture and grown to an ODeoo of 0.6. Cells were harvested by centrifugation at 6000 
rpm for 15 minutes at 4 °C, and the pellet was resuspended in 250 ml ice cold 50 mM 
CaCb before being incubated on ice for 20 minutes. The cells were harvested as 
before, resuspended in 25 ml of 50 mM CaCl2/20% glycerol and aliquoted into 
microcentrifuge tubes before being snap frozen in liquid nitrogen. Samples were 
stored in -70 °C and were viable for at least 2 months. Cells were thawed on ice prior 
to the addition of DNA.
2.2.6.2 Transformation of E.coli
The DNA to be transformed (usually a ligation mixture or around 100 ng of 
plasmid DNA) was added to 100 p.1 of competent cells, mixed gently and incubated 
on ice for 30 minutes. The cells were then heat shocked at 42 °C for 90 seconds and 
chilled by placing on ice for 2 minutes. 1 ml of pre-warmed LB was then added and 
the suspension was incubated at 37 °C for 1 hour. Each samples were pelleted by 
centrifugation at 12,000 rpm in a microcentrifuge for 2 minutes, resuspended in 100- 
200 p.1 of LB and plated onto selective medium and incubated overnight at 37 °C to 
allow the growth of the transformants.
2.2.7 Oligodeoxynucleotide Manipulation Techniques
2.2.7.1 Synthesis
Oligodeoxynucleotides used as primers were synthesized by L.Mesci (Bilkent 
University, Molecular Biology and Genetics Department) on Oligo lOOOM DNA 
synthesizer by utilizing cyanoethyl-phosphoramidite chemistry. After synthesis the
j?0
oligodeoxynucleotides were cleaved and deprotected by the UltraFast Cleavage and 
Deprotection BCit (Beckman) and dried by the SpeedVac (Beckman) before use.
2.2.7.2. Quantification
The concentration of the oligodeoxynucleotides were determined by using the 
oligodeoxynucleotide quantification option of the spectrophotometer.
The base composition of oligodeoxynucleotides can vary widely and therefore 
the molar extinction coefficient needs to be determined in order to make accurate 
estimations of the concentration, so the sequence of the oligos were entered to the 
spectrophotometer for the accurate estimation of the concentration
The concentration of the oligodeoxynucleotides was determined by using the 
equation;
^260" E (nsG + nsC + nsX + naA). C . 1
A260 is the absorbance at 260 nm 
C is the concentration in mM 
1 is the path length in cm
E is the sum of all the mM extinction coefficients of the nucleotides present 
n is the number of basés
The mM. extinction coefficient (s) values for the nucleotides are as follows: 
sdGTP=12.01, edCTP=7.05, sdATP=15.20, edTTP=8.40
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2.2.8.1 Agarose Gel Electrophoresis Of DNA Fragments
DNA fragments were separated by gel electrophoresis using agarose at 
concentrations of 0.8-1.5% w/v in IxTAE buffer (Maniatis et. al., 1982). Agarose 
was added at the desired amount and the sluny was heated until it got transparent. 
Then the liquid gel was slightly cooled and 0.2-0.4 p,g ethidium bromide per ml of gel 
was added for the visualization of the DNA bands. After the agarose has polymerized 
the sides and the comb of the apparatus were removed carefully and the gel was 
placed in the tank. TAE buffer was used as the running buffer and loaded to the tank 
till it covers the surface of the gel. A fifth volume of loading buffer (0.25% 
bromophenol blue, 0.25% xylene cyanol, 15% ficoll 400) was added to each sample 
and the sample were loaded to the gel. Electrophoresis was performed by running the 
gel for 1 hour at 100 V. The DNA bands were visualized by illuminating with UV 
light on a transilluminator at 302 nm. The gels were then photographed by Sony 
Video Graphic Printer UP-890CE.
2.2.8 Gel Electrophoresis
2.2.8.3 SDS Polyacrylamide Gel Electrophoresis
Electrophoretic separation of proteins under denaturing conditions was 
performed by following the methods described in Sambrook et. al. (1989). 12 and 
15% gels were made. The mini-gel glass plates were assembled according to the 
manufacturer’s instructions (BioRad). In order to prepare a 15% gel 5 ml of 
acrylamide-bisacrylamide (29:l(w/v%)), 2x resolving gel buffer pH 8.8, 200|il of 
10% ammonium persulphate and 9p.l of TEMED were mixed and poured into the gap 
between the glass plates. Sufficient space (the length of the comb teeth plus 1 cm)
5X
was left for the stackdng gel. Water saturated butan-l-ol or 99.5% isopropanol was 
layered onto the top of the gel. After the gel was settled and polymerized at room 
temperature the butan-l-ol layer was removed and the stacking gel (1 ml of 29:1 
acrylamide-bisacrylamide mixture, 2 ml ddH20, 3 ml 2x stacking gel buffer pH 6.8, 
180|j,l ammonium persulphate, and 6|il TEMED) was poured onto the top of the 
resolving gel. The comb was immediately inserted into the stacking gel, being careful 
to avoid formation of air bubbles. After 5-10 minutes the stacking gel was 
polymerized and the comb was removed carefully to form the wells. By using a 1 ml 
syringe the wells were washed to remove any unpolymerized acrylamide. 2x loading 
buffer was added to each sample at equal volume and the samples were then heated 
to 90 °C for 5 minutes to denature the proteins. The gel was mounted in the 
electrophoresis tank The Tris-glycine electrophoresis buffer was added to the top 
and the bottom reservoirs. The previously prepared samples were loaded into the 
wells. Gels were run for 30 minutes at 80V (creates a current of 20-30 mA through a 
single gel) until the samples leave the stacking gel and enter to the resolving gel. As 
the samples passed to the resolving gel the voltage was raised to 150V (creates a 
current of 30-40 mA through a single gel) and kept running for 60-90 minutes. The 
gel was then removed carefully and stained by Coomassie brilliant blue (0.25% 
Coomassie Brilliant Blue G250, 45% methanol, 10% acetic acid) for 20 minutes and 
destained in a solution of 30% methanol, 10% acetic acid and 60% deionized distilled 
water for 1-4 hours.
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The length of DNA fragments and the sizes of protein samples were estimated 
by comparing them to known molecular weight standards which had been run on the 
same gel,
a) DNA length markers: 0.5 mg a DNA digested with Hiruñll and ifcoRI or Ikb 
ladder (MBL Fermentas) were used as DNA markers. The sizes of the fragments 
are given in Figure 2.1.
b) Protein Markers: 24 and 14 kilodaJton markers from Sigma and 97.5, 66, 45, 31, 
21, 14 kilodalton markers from Pharmacia were used. Figure 2.2 shows the 
markers on the gel.
2.2.9 Automated Sequencing Of Double Stranded DNA
The automated sequencing of the construct was carried out on an ABI Prism 
377 sequencer by Birsen Cevher in Bilkent University.
2.2.10 Protein Expression And Purifícation
2.2.8.3 Electrophoresis Markers
2.2.10.1 Cell Growth And Induction
Small scale induction for initial screening of protein expression were 
performed by inoculating 5 ml of LB media with 200 jil of an overnight culture which 
had been inoculated from a colony on agar plate. For large scale inductions, 30 ml of 
media was inoculated with a colony and grown overnight. This was then used to 
inoculate 0.5-1 L of fresh media. The protein expression in E.coli cells carrying the 
expression plasmid was induced by the addition of IPTG to actively growing cells in 
LB at an ODôoo of 0.6-0.7. Incubation was continued for a further 4 hours. The
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Figure 2.1: DNA size markers used during the course of this study. Panel A; 1 kb 
DNA ladder and Panel B; Lambda DNA/£'c’oRI+/fwi/[II Marker, run 
on a 1% agarose gel.
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Figure 2.2: Protein size markers used during the course of this study. Panel A; 24 
and 14 kilodalton markers from Sigma. Panel B; 97.5, 66, 45, 31, 21, 
14 kilodalton markers from Pharmacia, were used.
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induction conditions varied depending on the vector and strain being used and are 
described in the relevant section of the text.
2.2.10.2 Cell Harvest And Lysis
Small scale cultures (up to 5 ml) were harvested by centrifugation at 13,000 
rpm for 2 minutes in a microcentrifuge. The amount to be pelleted for polyacrylamide 
gel electrophoresis analysis was calculated by the following equation;
V culture to be pelleted — 300 p.1 / ODfioo
Cell pellets were resuspended in 80 р,1 of 2x loading buffer (detailed in the 
relevant text) and boiled in 90 °C for 5 minutes before loading to the gel.
Larger volume samples (0.5-1 L) were harvested by spinning at 6000 rpm for 
15 minutes at 4 °C in a Beckman Avanti J-25I centrifuge, resuspended in the 
appropriate buffer and sonicated on ice by eight 15 seconds bursts at full setting. 
Soluble and insoluble samples were separated by centrifuging at 18,000 rpm for 35 
minutes at 4 °C in a Beckman Avanti J-25I centrifuge. The insoluble portion was 
resuspended in appropriate second buffer and incubated by continuous stirring at 
room temperature for 1 hour and then sonicated on ice by eight 15 seconds bursts at 
full setting. Again the soluble and insoluble samples were separated by centrifuging at 
18,000 rpm for 35 minutes at 4 °C in a Beckman Avanti J-25I centrifuge.
10-100 |il volumes of each soluble and insoluble samples were mixed with an 
equal volume of 2x SDS-PAGE loading buffer, boiled for 5-10 minutes and run on a 
SDS polyacrylamide gel.
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2.2.10.3 Protein Purification By Immobilized Metal Ion Affinity 
Chromatography
Proteins expressed by using the QlAexpress (Qiagen) pQE expression vector 
system carry a stretch of 6 consecutive histidine residues fused to their amino 
terminus (His-Tag), which allows for affinity purification using nickel ions 
immobilized on a metal chelation resin. Elution of the bound protein is made by 
imidazole or by lowering the pH. Purification could be carried out under native 
conditions or, if the protein is insoluble, under denaturing conditions. The basic 
protocols used are described in the Qiagen QlAexpress Handbook (1992).
The Ni-NTA resin is composed of nickel ions (Ni  ^^ ) immobilized on nitrilo- 
tri-acetic acid (NTA) ligand which has four chelating sites that can interact with the 
four coordination sites of the Ni^”". The two other coordination sites are left for 
interaction between the His-Tag and the N P. The Ni-NTA resin was kept as 50% 
slurry in 20% ethanol solution at 4°C for long term storage. 8 ml resin slurry was 
pretreated as described by the producer, before incubation with the solubilized 
protein mixture by continuous stirring for 1 hour at room temperature or 4 °C 
according to the content of the buffer in which the cells were sonicated. Columns 
were made from 5 ml syringes plugged with glass cotton. The resin-protein mixture 
was slowly loaded to the column and the down flow was collected in a labeled tube 
for further analysis. After the resin is settled and all the unbound protein solution 
drained out the resin was washed by 20 ml Buffer C containing 1 mM imidazole to 
decrease nonspecific interactions. Step elution with Buffer C containing the following 
concentrations of imidazole and the elutes were collected in 1.7 ml microcentrifiige 
tubes labeled from 1 to 60;
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Table 2.3: Conditions of step elution in purification of a histidine tagged protein
Imidazole Concentration 
(mM)
Volume Used (ml) Elutes collected
2 10 1-6
4 10 7-12
8 10 13-18
16 10 19-24
32 10 25-30
64 10 33-36
128 10 37-42
256 10 43-48
400 10 49-54
500 20 55-60
The column was later washed with 20 ml Buffer C containing 1 M imidazole 
to strip down the remaining proteins in the column.
Purification was carried out in similar manner for both native and denaturing 
conditions with the following changes.
■ all buffers used under denaturing conditions contained 8 M urea
■ protease inhibitor PMSF was added to the solutions used for native purification
■ all steps of native purification are carried out in the cold room (0-4 °C), and the 
denaturing purification steps were carried out at room temperature.
The purity and the protein content of the elutes were checked by SDS-PAGE 
electrophoresis. As the elutes were containing imidazole they were incubated at 37 
°C for 10 minutes after adding loading buffer in order to avoid imidazole mediated 
cleavage of labile bonds.
2.2.10.4 Concentration of the Purified Protein
The protein samples purified under denaturing conditions were renatured by 
dialyzing against PBS containing 0.1% Tween 20 to remove urea from the protein
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mixture. The dialysis bag was then treated with aquasid to remove excess water from 
the mixture and to concentrate the protein. The concentrated protein was again 
dialyzed against 55% glycerol in PBS containing 0.1% Tween 20, to further 
concentrate the protein and to enable storage at -20 °C. All dialysis and concentration 
steps were carried out at 4 °C.
2.2.10.5 Protein Quantification
Protein concentration was determined by Bradford (1976) method by using 
the BioRad protein assay kit. A standard curve was prepared by using bovine serum 
albumin (BSA) at known concentrations (1.34 p.g/pl) and the concentration of the 
unknown protein sample was determined from this.
2.2.11 Immunological Detection of Immobilized Proteins (Western Blotting)
2.2.11.1 Transfer of Proteins onto Membranes
After performing SDS-PAGE electrophoresis, the proteins were transferred 
from the gel to a Sigma Immobilon-P polyvinylidene difluoride membrane. The 
transfer was performed by applying an electric field to the gel and the membrane 
vertically by BioRad Transferblot SD. First four pieces of 3 MM Whatman paper and 
a piece of transfer membrane were cut at the size of the gel. To increase the transfer 
efficiency the transfer membrane cut at the size of the gel was soaked into 10 ml of 
methanol and was shook for 10 minutes and washed with ddH20. The Whatman 
papers and the transfer membrane were then soaked into transfer buffer and shook 
for 20 minutes. After the gel has been removed from the electrophoresis glass plates, 
the Western sandwich, as shown in the Figure 2.3, was established by avoiding
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formation of any air bubbles between the layers, 10 V of potential difference was 
applied to the Transferblot SD apparatus for 45 minutes. After the transfer has been 
completed the membrane was washed with 30 ml PBS twice.
2.2.11.2 Immunological Detection of Immobilized Proteins
The membrane was incubated in 50 ml of blocking solution A for overnight 
with continuous shaking at 4 °C. After blocking, the membrane was washed with 
PBS containing 0.05% Tween 20 (PBST) for 10 minutes three times. The membrane 
was then incubated in blocking solution B containing the primary antibody for 1 hour. 
The membrane treated with primary antibody was washed with PBST for 10 minutes 
three times. The washed membrane was then treated with secondary antibody in 
blocking solution B for 1 hour and it was again washed with PBST for 10 minutes 
three times. Due to the enzymatic characteristic of the secondary antibody the 
detection step differs.
The immunodetection in horse reddish peroxidase (HRP) conjugated 
secondary antibodies were carried out by using the Amersham LIFE SCIENCE ECL 
Western blotting detection reagents, according to the producers instructions and the 
bands were visualized by exposing the membrane on photograph films. The alkaline 
phosphatase conjugated secondary antibodies were detected by NBT-BCIP substrate 
system. The membrane was developed in 10 ml of substrate buffer containing 330 
|ig/ml of NBT and 170jig/ml of BCIP and the bands became visible within 3 minutes.
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Figure 2.3: Western Blotting sandwich
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2.2.12 Indirect Enzyme-Linked Immunosorbent Assay (ELISA) to detect
specific antibodies
The sera of the patients were screened by ELISA technique described in 
Maniatis et. al., (1982) with slight modifications. This assay enables the screening of 
antisera for specific antibodies when milligram quantities of purified or semi purified 
antigen are available. Antibodies were detected by coating the wells of microtiter 
plates (96 wells. Nunc) with 100 ng/well of the antigen in PBS containing 0.02% 
NaN3 overnight. The coated plates were incubated first with 200 pl/well blocking 
solution C for 1 hour and then with blocking solution C containing sera (diluted 200 
times) for another 1 hour and washed with PBST (0.1% Tween 20) three times after 
each of these steps. Blocking solution C containing alkaline phosphatase conjugated 
antibodies (Sigma Immuno Chemicals, 1/30,000 dilution) against the human IgG, 
IgM, IgA was then dispensed as 200 p.l/well. After incubating for 1 hour at room 
temperature, unbound conjugate was washed three times with PBST and 200 pl/well 
substrate solution containing 1 mg/ml PNPP was added. The amount of substrate 
hydrolyzed was assessed by Beckman Biomek 2000 automated laboratory 
workstation, by reading the absorbance at 450 nm, after incubation in dark for 1 to 2 
hours at room temperature.
2.3 STANDARD SOLUTIONS AND BUFFERS
2.3.1 Mini Preparation solutions
Solution 1:
50 mM Glucose 
25 mM Tris.Cl (pH 8.0)
5 2 ,
lOmMEDTA (pH 8.0)
Solution I can be prepared in batches of approximately 100 ml, autoclaved 
and stored at 4 °C.
Solution II
0.2 M NaOH (freshly diluted from 10 M stock solution)
1% SDS ( freshly diluted from 10% stock solution)
Solution III
5 M Potassium Acetate 
Glacial Acetic Acid 
Distilled Water
60 ml
11.5 ml
28.5 ml
The resulting solution is 3 M with respect to potassium and 5 M with respect to
acetate
2.3.2 Electrophoresis Buffers
TAE Buffer:
Working Solution 
0.4 M Tris acetate 
0.001 M ED IA
50x Stock Solution (lit)
2 M Tris Base (242 g)
57.1 ml Glacial Acetic Acid 
50 mM EDTA
2x Resolving Gel Buffer
750 mM Tris-HCl, pH 8.8 
0.2% SDS
2x Stacking Gel Buffer
250 mM Tris-HCl, pH 6.8 
0.2% SDS
2x SDS-PAGE Loading Buffer
25.6% Glycerol 
9.8% (5-Mercaptoethanol 
4.5% SDS
1.5% Tris-HCl, pH 6.8
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0.006% Bromophenol Blue
5x Electrophoresis Running BufTer
125 mM Tris 
1.25 M Glycine 
0.1% SDS, pH 8.3
2.3.3 Protein Solubilization and Purification Buffers 
Sonication Buffer
50 mM NaP0 4  Buffer (93% dibasic, 7% monobasic)
300 mM NaCl 
10% Glycerol
Buffer B
50 mM NaP0 4  monobasic 
300 mM NaCl
pH 8.0 (adjusted by NaOH titration)
For purification under denaturing conditions 8 M urea was added to the above 
solution.
Buffer C
50 mM NaP0 4  monobasic 
300 mM NaCl
pH 6.0 (adjusted by HCl titration)
For purifications under denaturing conditions 8 M urea was added to the above 
solution.
2.3.4 Western Blotting and ELISA Buffers
Phosphate Buffered Saline (PBS)
150mMNaCl 
16 mM Na2HP0 4  
4 mM NaH2P0 4 , pH 7.4
Blocking Solutions
6 ^
i) Blocking Solution A
10% Skim Milk Powder 
0,2% Tween 20 
in PBS, pH 7.4
ii) Blocking Solution B
5% Skim Milk Powder 
0,2% Tween 20 
in PBS, pH 7.4
iii) Blocking Solution C
5% milk powder
0.02% NaNa 
in PBS, pH 7.4
Substrate Buffer for Alkaline Phosphatase Conjugated Antibodies
100 mM Tris
lOOmMNaCl
16mMMgCl
The pH of the resulting solution should be around 9.5.
Transfer Buffer
50 mM Tris 
40 mM Glycine 
0.075% SDS 
20% Methanol
The pH should be around 9.0-9.4. Never adjust the pH with acid or base.
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3. RESULTS
3.1 CLONING OF HEPATITIS C VIRUS CORE REGION
3.1.1 Hepatitis C Virus Core Region
Hepatitis C virus core region is the first gene (5’^ 3 ’) of the open reading 
frame (ORF) of its genome. Core region begins with the start codon (AUG) which is 
the start codon for the entire polyprotein chain. Core region lies between nucleotides 
342-915 of the viral genome in many isolates. It is the most highly conserved region 
of the ORF however sometimes isolates might show as much of difference as 20%. 
The core region sequences of some isolates belonging to different genotypes is 
aligned and presented in Appendix A.
The core protein is the putative nucleocapsid component of the virion, and as 
it is highly basic in nature, it probably corresponds to the C protein found in 
flavivimses. The nucleotide and the amino acid sequence of the core is well 
conserved among different HCV isolates (Bukh et al., 1994). The core protein is 
located at the amino terminus of the polyprotein sequence and is followed by the two 
envelope proteins El and E2 and then by the non-structural proteins. The carboxyl 
terminus of the core protein has been localized to amino acid 191 of the polyprotein 
sequence by in vivo and in vitro translation studies. The cleavage between the core 
and the El envelope protein is believed to be mediated by the signal peptidase 
located in the lumen of the endoplasmic reticulum (ER) (Hijikata et al., 1991a). There 
are two hydrophobic segments in the carboxyl half of the protein: one (approximately
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at amino acids 170-191) is considered to correspond to,the signal sequence for the 
translocation of El into the ER; the second (amino acids 121-151) may be involved 
in membrane binding.
The full length protein, known as p22 has been identified both in vivo and in 
vitro (Hijikata et al., 1991a) but a second species pl9 generated by a second cleavage 
at amino acid 173 is the major product observed following expression in mammalian 
cells (Santolini et al., 1994; Moradpour et al., 1996), Both p22 and pl9 are located at 
the ER membrane and the conversion of p22 to pl9 is presumably mediated by 
membrane associated cellular enzymes. A third collinear species of core which can 
also be detected in expression studies (Lo et al., 1995) is approximately 151 amino 
acids long (p i6) and appears to be localized in the nucleus and more specifically in 
the nucleolus. The relative expression of pl6 varies between different strains of HCV 
and suprisingly due to the nature of the amino acid at position 9 of the protein (Lo et 
al., 1994). The distinct difference in subcellular localization between pl6 and pl9/p22 
suggests that the biological role of pl6 may be different. In particular the nucleolar 
localization of pl6 may be due to its ability to bind to ribosomes, which are 
assembled in the nucleus (Santolini et al., 1994). More recent reports have indicated 
additional cleavage species at 179 and 182 which are not dependent on prior cleavage 
at 191 (Hussy et al., 1996). It is currently unclear what roles these diverse core 
proteins play in virus morphogenesis.
As the virion nucleocapsid formation involves multimerization of core protein 
and its interaction with viral RNA, these characteristics have been studied extensively 
and specific functions have been mapped to discrete portions of the protein (Figure 
3.1).
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Figure 3.1: The hydrophobicity plot and the interaction 
domains of the hepatitis C virus core 
protein (Nolandt et al; 1997)
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Besides the primary function of core protein in the encapsulation of the virus, 
it is also reported to play important roles in modulation of the host’s gene expression, 
A lot of data have been accumulated indicating that HCV core protein is a trans­
acting regulatory protein. The 22-kDa core protein trans-suppressed CAT gene 
expression under the control of various promoters (Ray et al, 1995; 1997; 1998). It 
was reported to regulate the replication and the expression of the HBV genome (Shih 
et al., 1993) and to trans activate c-myc oncogene (Ray et al,, 1996a). It also 
enhanced the H-ras oncogene activity in immortalizing rat embryo fibroblast (Ray et 
al., 1996b). Hepatitis C virus core protein is also shown to repress 
promoter activity (Ray et al., 1998). A very recent study (Matsumoto et al., 1997) 
showed that the HCV core protein interacts with the cytoplasmic tail of the 
Lymphotoxin-P receptor as well as with the TNF receptors. This result implicates 
that HCV core protein is a potential modulator of the host immune system and it is 
involved in a mechanism for viral evasion of host defenses, perhaps allows for viral 
persistence.
3.1.2 Cloning Strategies for the Production of Recombinant Hepatitis C Virus 
Core Protein
In order to express and purify the hepatitis C virus core protein we have 
cloned the core region, amplified by PCR from a cDNA, synthesized by using the 
viral RNA isolated from a chronic hepatitis C patient’s sera, into pQE30 expression 
vector which belongs to pQE family of expression vectors (Qiagen). BamWi and 
Hindill restriction enzyme sites were introduced to the ends of the core region 
during amplification and these sites which are also found in the multiple cloning site
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of the pQE30 plasmid were used to clone the core region into the vector. The 
resulting clone was isolated and named as pQE30CORE.
3.1.2.1 pQE Vectors
The pQE plasmids belong to the pDS family of plasmids (Bujard et al., 1987) 
and were derived from plasmids pDS56/RBII and pDS781/RBSII-DHFRS (Stuber et 
al., 1990). The pQE expression vectors provide high-level expression in E.coli of 
proteins or peptides containing 6xHis affinity tag. There are several ways to create a 
QIAexpress-type expression construct. The tag may be placed at the N terminus 
(Type IV); at the C terminus (Type III) or at the C terminus of a protein utilizing its 
original ATG start codon (Type ATG). If small peptides are to be synthesized, they 
can be fused to mouse DHFR (Type II), where the poorly immunogenic DHFR 
stabilizes the peptide during expression and enhances antigenicity.
The pQE vectors contain the following elements in common.
• an optimized, regulable promoter operator element, consisting of the E.coli phage 
T5 promoter and two lac operator sequences.
• a synthetic ribosome binding site, RBSII, designed for optimal mRNA recognition 
and binding.
• optimized 6xHis affinity tag coding sequence.
• a multiple cloning site.
• translation stop codons in all three reading frames.
• the transcriptional terminator ‘to’ from phage lambda.
• the replication region and the gene for ß lactamase of plasmid pBR322.
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Type IV constructs which place the 6xHis tag at the N terminus of the protein 
are most commonly used ones and they do not require the coding sequence to bear a 
stop codon in frame because they themselves contain stop codons 3 ’ to the polylinker 
sequence in all three reading frames. Moreover, in the pQE expression vectors, Type 
IV proteins are often expressed 2-4 times more efficiently then Type 3 and Type 
ATG constructs. Also as the N terminus of the core protein is highly basic in nature 
and the C terminal is rather hydrophobic, placing the 6xHis tag at the N terminus 
would have improve its exposure to the Ni-NTA resin. Figure 3,2 shows the Type IV 
pQE expression vectors (pQE30,31,32) and their multiple cloning sites.
pQE30 was chosen as the cloning and expression vector for this study. The 
first restriction enzyme site BamYQ. is in frame with the start codon (Figure 3.2). The 
core region sequence from various isolates were searched by computer for the 
restriction enzyme sites available at the multiple cloning site of the plasmid and no 
internal BamHL and Hindill sites were found in the core region. Therefore two 
enzymes were chosen to be introduced to the ends of the core region which is to be 
cloned by PCR (BamWl to the 5’ and HincBll to the 3’ end of the gene).
3.1.2.2 Plasmid Design
Two different restriction enzyme sites at the 5’ and 3’ end of the core region which is 
to be cloned were required. As mentioned before 5a?wHI and Hindill restriction 
enzymes were chosen to be used during the cloning of the region. These sites were 
introduced to the ends of the core region, during PCR amplification of the core 
region. In order to digest the PCR product with the restriction enzymes at least 3 
nucleotides preferably C or G must be placed upstream of the restriction enzyme site
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Figure 3.2: General features of Type IV pQE expression vectors, and their multiple 
cloning sites.
so both the forward and reverse primers was designed to have CGC sequence on 
their 5’.
Amplification of the viral sequences from a source, where the exact 
nucleotide. sequence is not known, is rather difficult as the RNA viruses and 
especially HCV has a high mutation rate and therefore a high rate of variation. As a 
first attempt a previously reported HCV sequence; HCV Prototype la (Choo et al., 
1989) was used as the template designing in the primers and a pair of primers were 
synthesized for the amplification of the core region which encodes for the amino 
acids 1 to 191 of the polyprotein chain. However after numerous amplification 
attempts the primers were replaced with a second set.
The second set of primers were designed by aligning the nucleotide sequences 
from various Genebank entries made for the core region of the HCV genome. The 
divergence of the sequence at the 5’ end of the core protein was rather small, so the 
sequence given in Figure 3.3. A, was chosen as the forward primer. The 3’ end of the 
core region however was very divergent from one isolate to the other even with in 
the same genotype, so a more conserved region closest to the end of the gene was 
searched and the sequence was found to be more conserved in the region which is 5’ 
to the codon encoding the 179“* amino acid, so the reverse primer shown in Figure 
3.3.B, was designed. Both the forward and reverse primers are degenerate at the 
positions marked with red because both G and A bases were commonly occur at that 
positions among the isolates. More attention was paid to the sequence of the isolates 
from genotype lb as there are some unconfirmed data mentioned in a couple of 
articles stating that the HCV lb subtype is the most common among Turkish 
population.
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A) TC 145: Core Forward
CGCGGATCCATGAGCAC(G/A)AATCCTAAACC
BamWi site +1
B) TC 146: Core Reverse
CGCAAG CTTGAGGAAGATAGA(G/A)AAAGAGCAACC
site +178
Figure 3,3: Primers designed for amplifying the core region. Panel A; TC 145 the forward 
primer. Panel B; TCI46 the reverse primer.
3.1.3 Amplification of the Core Region from the viral RNA Isolated from a 
Patients Sera
3.1.3.1 RNA Isolation and cDNA Synthesis
The hepatitis C vims RNA was isolated from a chronic hepatitis C patients 
sera provided by the Gastroentrology Department of Çukurova University, Adana, 
Turkey, by using the single step guanidinium thiocyanate method (Ausbel et al., 
1991) with slight modifications (Wilson et al., 1995) as described before (Section 
2.2.1). The isolated RNA was then reverse transcribed to generate the cDNA. 
Stratagene RT-PCR Kit was used for cDNA synthesis and the reaction was 
performed as the manufacturer’s instmctions by using the random hexamer primers 
supplied by the manufacturer. OligodT primers were not used for the reverse 
transcription because it has been shown that many of the HCV isolates lack poly-A 
sequence at their 3 ’ end.
3.1.3.2 First Strand PCR
The cDNA synthesized from the isolated viral RNA was then used as the 
template and a PCR reaction was set as follows:
5 pi cDNA
5 pi lOx Taq Polymerase Buffer 
3 pi MgCİ2 (25 mM)
2 pi primers each (from 50 pmol/pl stocks)
0.4 pi dNTP mix (from 100 mM stock)
0.3 pi Taq Polymerase (4 u/pl)
32.3 pi ddHzO
50 pi Total Reaction Volume
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Taq Polymerase was added to the tube after incubating the PCR mix at 94 °C
for 6 minutes to make a hot start. The thermal cycler was programmed as below:
94 °C for 6 minutes -> Hot Start ^
50 °C for 1 minute | Pre-PCR
72 °C for 1 minute )
94 °C for 45 seconds
55 °C for 45 seconds I 30 cycles
72 °C for 45 seconds )
72 °C for 7 minutes 
4 °C forever
As the primers contained restriction enzyme sites which were not complement 
to the cDNA sequence, a pre-PCR step was performed before the regular PCR cycles 
to enhance the annealing of the primers during the first round of PCR by applying a 
lower annealing temperature (50 °C). Figure 3.4 shows the result of the first strand 
PCR made from the cDNA. The expected size of the PCR product was 550 base 
pairs and the first PCR band is visible, by ethidium bromide staining, after running on 
a 1.5% agarose gel, at the expected size.
3.1.3.3 Second PCR
In order to increase the quantity of the PCR product to be able to use it for 
cloning a second PCR was set. As the first strand PCR product contained high 
concentrations of DNA the second PCR reaction should be optimized. The following 
optimization was made;
Table 3.1; Optimization of second PCR conditions
First strand PCR Product (|il) 1 0.8 0.6 0.4
MgCl2 (25 mM) (til) 2.5 2 1.5 1
Primers (from 50 pmol/|il stocks) (p.1) 0.8 0.8 0.8 0.8
lOx Taq Polymerase Buffer (pi) 5 5 5 5
dNTP (100 mM) (pi) 0.4 0.4 0.4 0.4
Taq Polymerase (4u/^l) (|il) 0.2 0.2 0.2 0.2
ddH20 (pi) rest rest rest rest
The optimum PCR mix for the second PCR was found to be;
0.4 jil of the First Strand PCR Product 
5 p,l 1 Ox Taq Polymerase Buffer 
2 |ul MgCl2 (25 mM)
0.8 |il primers each (from 50 pmol/pl stocks)
0.4 |il dNTP mix (from 100 mM stock)
0.2 fil Taq Polymerase (4 u/p.1)
40.6 111 ddH20
50 111 Total Reaction Volume
The conditions programmed on the thermal cycler was different from the first
PCR in order to improve the specificity of the reaction and to avoid smear bands. The
conditions were;
94 °C for 5 minutes Hot Start 
94 °C for 45 seconds ^
55 °C for 30 seconds i 25 cycles 
72 °C for 30 seconds )
72 °C for 7 minutes 
4 °C forever
Figure 3.5 shows the result of the second PCR made by using the first strand PCR as 
the template. The expected size of the PCR product was 550 base pairs and the 
second PCR band is visible, by ethidium bromide staining, on 1.5% agarose gel at the 
expected size.
3.1.4 Cloning of the PCR Fragment Carrying the Core Region into the 
pQE30 Plasmid Vector
All of the second PCR product was loaded and run on a 1.5% agarose gel. 
The band was carefully cut from the gel and then was purified by using the Qiagen 
Gel Extraction Kit and was eluted in 16p.l ddH20. The amplified PCR fragment was 
carrying BamYiL restriction enzyme site on its 5’ end and HiruUll restriction enzyme 
site on the 3’ end. These sites were also available on the multiple cloning site of the
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3.4: First strand PCR of core 
region by using primers 
TCI45 and TCI46 and the 
cDNA synthesized by RNA 
isolated from patient 8’s serum
X EcoRl/Hindni Marker 
Negative Control 
Positive Control; 5’UTR 
amplified by primers TC 62/63 
Core region amplified by 
TC145/146
Figure 3.5: Second PCR of core region by 
using primers TCI 45 and 
TCI46 and the first strand 
PCR.
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pQE30 plasmid vector. Figure 3.6,A, schematically represent the amplified PCR 
fragment and Figure 3.2 shows the multiple cloning site of pQE30. Further DNA 
manipulation techniques were used on the PCR product and the vector to make the
construct.
3.1.4.1 Restriction Enzyme Digestion
All of the eluted second PCR product was double digested with BamWl and 
HincUll (MBI Fermentas) at 37 °C overnight. The digestion mix was set as described 
below:
16 pi PCR product recovered from agarose gel 
1 pi Bamlil Restriction Enzyme (10 units/pl)
1 pi Hindlll Restriction Enzyme (10 units/pl)
2 pi lOx BamHL Buffer (MBI Fermentas)
0.2 pi Bovine Serum Albumin (from 100 mM stock)
20 pi Total Digestion Volume
All of the digestion product was run on a 1.5% agarose gel and Figure 3.8 
shows the band of digestion product of the PCR fragment at its expected size around 
550 base pairs. The band was cut from the agarose gel and the digested PCR product 
was recovered from gel by using Qiagen Gel Extraction Kit (Qiagen).
The midi scale preparation of the pQE30 plasmid vector was made by using 
the Qiagen Plasmid Isolation Kit (Qiagen). 1 pg of this midiprep pQE30 vector was 
cut with Bam¥Q. and Hindlll at 37 °C for 4 hours. The digestion mix was set as 
described below:
7 pi pQE30 midiprep (Ipg)
1 pi BamHl Restriction Enzyme (10 units/pl)
1 pi Hindlll Restriction Enzyme (10 units/pl)
2 pi lOx BamHl Buffer (MBI Fermentas)
0.2 pi Bovine Serum Albumin (from 100 mM stock)
9 pi ddH20
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A)
ВатШ site 
CGCGGATCC 
GCGCCTAGG
A T ^
TAG A.As 1-178
Hindlll site 
AAGCTTGCG 
TTCGAACGC
B)
ATGAGAGGATCG(CAC)6WArcdATG A As 1 1 7 0  CTcI a AGCTTAATTAG 
Start 6xHis BamHI 1 1 - 1/0 I ШпсШ1 Stop
Figure 3.6; Schematic presentation of; A) The PGR product carrying the BamHI and 
Hindlll restriction enzyme sites on its 5’ and 3’ ends respectively; B) The 
ligation product of the PGR fragment and the pQE30 plasmid vector.
8 0
20 |il Total Digestion Volume
All of the digestion product was run on a 0.8% agarose gel and Figure 3.7 
shows the band of digestion product of the pQE30 plasmid vector at its expected size 
around 3500 base pairs. The band was cut from the agarose gel and the digested 
pQE30 plasmid vector was recovered from gel by using Qiagen Gel Extraction Kit 
(Qiagen).
3.1.4.2 Ligation of the Core Region into pQE30 Plasmid Vector
The recovered digestion products of PCR of core region and pQE30 plasmid 
vector were used in setting the ligation reaction. Ligations were performed in 15 pi 
reaction volume containing around 0.5 pg of pQE30 cut with BamYQ. and Hindlll 
and molar excess of insert (core region amplified by PCR and cut with BamUl and 
Hindlll). 3 Weiss units of T4 ligase and standard ligation buffer supplied with the 
enzyme was added and the ligations were incubated at room temperature for 4 hours. 
Also a religation control reaction was set which contains the same amount of the 
digested plasmid but did not contain the insert. The ligation mixtures were set as 
below:
8 pi PCR product cut with BamHl and Hindlll and recovered
2 pi pQE30 cut with BamYH and Hindlll and recovered (around 0.5 pg)
1 pi T4 Ligase (3 units) (MBI Fermentas)
1.5 pi lOx T4 Ligase Buffer (MBI Fermentas)
3.5 pi ddH20
15 pi Total Ligation Volume
Religation control contains 11.5 pi ddH20 and no insert.
All of the ligation mixtures were JM109 cells were transformed with the
ligation product, by using the method described earlier. The transformed cells were
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onto LA plates containing 100 pg/ml ampicilin for selection. A transformation 
control was also made by spreading competent cells without adding any DNA onto 
the LA plates containing ampicilin. The plates were incubated at 37 °C for overnight. 
There were three colonies on the ligation plate and there were not any colonies on 
the religation and transformation control plates.
3.1.4.3 Selection of the Correct Clone
Expression vectors such as the pQE plasmids do not provide color selection 
for plasmids that contain inserts after ligation and transformation. In order to find the 
correct clone mini scale plasmid purification was made for all three colonies present 
on the ligation plate. The three colonies on the ligation plate were then inoculated 
into 5 ml LB containing 100 p.g/ml ampicilin and were incubated with continuos 
shaking at 37 °C overnight, until the cultures became saturated. 1.5 ml from each 
saturated culture were pelleted and mini scale plasmid purification was carried out, 
using the method described before.
7 |j,l of the mini-preparation DNAs were then digested with BamYQ. and 
HiruñW restriction enzymes in order to understand whether the plasmids carry the 
insert or not. The digestion mixture was incubated at 37 °C for 4 hours and all of the 
digestion products were loaded on a 1% agarose gel and run (Figure 3.9). All three 
colonies were shown to contain the pQE30 vector carrying the core region insert.
3.1.4.4 Midi Scale Preparation of the pQE30 Clone Carrying Core region
80 ml LB containing 100 pg/ml ampicilin were inoculated with colony 2 from 
the ligation plate and was incubated at 37 °C with continuos shaking for overnight.
31
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Figure 3.9: Selection of the correct clone among 
the three ligation colonies.
Lanes:
1. 1 kb DNA ladder marker
2. pQE30 cut with BarnW Hindlll
3. Miniprep of ligation colony 1 cut with 
BamWJHindlW
4. Miniprep of ligation colony 2 cut with 
BarnmiHindm
5. Miniprep of ligation colony 3 cut with 
BammiHindlll
The cells were pelleted by centrifuging at 6000 rpm for 15 minutes and the midi scale 
plasmid isolation was performed by using QIAfilter plasmid midi kit (Qiagen), 
according to the manufacturers instructions. The resulting concentration of the 
plasmid DNA was 200 ng/pl.
3.1.3 Sequencing of the Clone
The automated sequencing of the construct was carried out on an ABI Prism 
377 sequencer by Birsen Cevher in Bilkent University. However due to an inhibiting 
factor the sequencing reactions performed were not efficient and a clear sequence of 
the clone was not achieved. The most clear sequencing results corresponding to the 
first 450 nucleotides long sequence of the clone is presented in Appendix B. This 
sequence was then translated and the amino acid sequence of the clone was then 
aligned with the sequences of the commercial core antigens (Appendix C).
The genotype of the patient 8, whose sera was used for cloning the core 
region, was not known at the start, but the 5’UTR of patient 8 was amplified and 
genotyped by E.Yildiz, Molecular Biology and Genetics Department, Bilkent 
University. The patient was found to be infected with type lb hepatitis C virus.
3.2 EXPRESSION AND PURIFICATION OF THE CORE PROTEIN
3.2.1 Qiaexpress E.coli Protein Expression System
Expression from the Qiaexpress protein expression vector’s 
promoter/operator region (Kcoli phage T5 regulated promoter containing two lac 
operator sequences) is extremely efficient and can only be prevented by the presence 
of high levels of lac repressor. The E.coli host cell M l5 was used in this study for
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protein expression as it contains multiple copies of the plasmid pREP4, which carries 
the lad  gene encoding the lac repressor. Multiple copies of pREP4 present in M l5 
cells ensure high levels of lac repressor and tight regulation of protein expression. In 
order to maintain the pREP4 plasmid in the M l5 host cells, 25-30 pg/ml of 
kanamycin was added to the culture media for selection as well as the 100 p.g/ml of 
ampicilin used for the selection of the pQE30COR£ plasmid.
Expression from the pQE vectors is rapidly induced by the addition of IPTG, 
which inactivates the repressor and clears the promoter. The special ‘double 
operator’ system in the pQE vectors in combination with the high levels of lac 
repressor provided by pREP4, permits some control over the level of expression. The 
high levels of lac repressor can be reduced with low amounts of IPTG, leading only 
partial clearing of the promoter and concomitant low level transcription if desired.
In order to continue with the expression studies 100 ng of the construct 
PQE30CORE DNA from the midiprep was transformed into M l5 by using the 
method described before.
3.2.2 Small Scale Induction of the Core Protein
In theory all the Ml 5 cells carrying the pQE30CORE plasmid should have the 
ability to express the core protein when induced by IPTG, however the expression 
ability of each colony is not the same so a colony which expresses the core protein 
most efficiently must be selected among the colonies on the plate. For this reason 4 
colonies were chosen from the transformation plate and a small scale induction was 
carried out at 37 °C and the protein expression was induced by ImM IPTG.
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Selected colonies were inoculated into 5 ml LB, containing 100 |ig/ml 
ampicilin and 30 ^g/ml kanamycin for selection, and were grown at 37 °C overnight. 
1.25 ml of these saturated cultures were added to 8.75 ml of LB, containing 100 
(ig/ml ampicilin and 30 p.g/ml kanamycin, then grown at 37 °C until ODr,oo was 
around 0.6-0.7. Then the core protein expression in the cultures were induced by 
adding IPTG with a final concentration of ImM. Samples were taken before 
induction and 1, 2, 4, 6 hours after induction from each colony. The amount to be 
taken as sample for polyacrylamide gel electrophoresis (PAGE) analysis was 
calculated as 300 p,l / ОВбоо.
The samples were pelleted and the pellets were stored at - 20 °C until they 
were used for PAGE analysis. The Figures 3.10 and 3.11 shows the PAGE analysis 
of some of these samples. Expression was present in all of the colonies and it was 
maximum after 4 hours of induction. However colony 3 seemed to be the best 
expressing colony. Glycerol stocks were made, as described earlier in section 2.1.5, 
from this colony for further expression studies. The size of the expressed protein was 
checked and it was found to be around 22 kDa as expected (Figure 3.10 and 3.11).
3.2.3 Small Scale Purification Of The Core Protein
Core protein expression in a 3 ml bacterial culture was induced with 1 mM 
IPTG for 4 hours. The cells were pelleted and lysed in 300 p.l Buffer B (50 mM 
NaP0 4  monobasic 300 mM NaCl, pH 8.0) containing 8 M urea by vortexing and 
stirring at room temperature until the mixture in the tube became clear. 100 p.1 of Ni- 
NTA resin slurry was washed with 500 p,l of ddH20 and then equilibrated with 500 
|il of Buffer B containing 8 M urea. The mixture was centrifuged at 13,000 rpm for
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1 2 3 4 5
Figure ЗЛО: Small scale induction with expression colony 
3. Lanes 1 to 4 shows the samples taken at 0, 
2, 4, 6 hours of induction, respectively. Lane 
5 is 24 kDa marker. The arrow shows the 22 
kDa expressed core protein.
Figure 3.11: Small scale expression colonies. Lanes 1 to 4 
shows the 4 hour induction samples from 
expression colonies 1 to 4 respectively. Lane 
5 is uninduced Ml 5 cells containing the 
expressing plasmid. Lane 6 and 7 are protein 
size markers 14 kDa and 24 kDa.
30 seconds on a bench top microfuge, and the supernatant was discarded then the 
resin was resuspended in 50 p,l Buffer B containing 8 M urea and added to the lysed 
cells. The resin and the bacterial lysate was incubated with continues stirring at room 
temperature for 30 minutes, then centrifuged at 13,000 rpm for 2 minutes in a bench 
top microfuge. The supernatant discarded then the resin was washed with 300 |il of 
Buffer C (50 mM NaP0 4  monobasic, 300 mM NaCl, pH 6.0) containing 8 M urea for 
2 times. At the end resin was resuspended in 30 p.1 of Buffer C containing 8 M urea 
and 0.1 M EDTA. EDTA has the ability to chelate divalent ions like Ni^  ^ so the Ni^  ^
as well as the bound core proteins were eluted. The mixture was spun down and the 
supernatant carrying the core protein was removed. 15 p.1 of the purified protein was 
loaded on a 15% SDS polyacrylamide gel. Figure 3.12 shows the small scale purified 
core protein.
3.2.4 Optimization Of The Core Protein Expression
The growth temperature affects the protein expression and especially the 
correct folding of the recombinant protein, thereby its solubility, so three growth 
temperatures 25 °C, 30 °C and 37 °C were tried during the expression studies. Also 
the ODeoo value at the induction point and the EPTG concentration used for induction 
were critical in expression. The combination of these conditions were tried as 
summarized on the Table 3.2 below. The samples were taken after 4 hours of 
induction and 6 hours of induction.
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Table 3.2: Optimization of core protein expression conditions
Induction
Temperature
(°C)
Induction ООбоо
IPTG
Concentration
(mM)
37 0.4 0.3
37 0.6 0.1
37 0.6 0.2
37 0,6 0.3
37 0.6 1
30 0,4 0.3
30 0,6 0.1
30 0.6 0.2
30 0.6 0.3
25 0.4 0.3
25 0.6 0.3
Expression
Intensity
+++++ 
+ 1111 
+++++ 
+++++
As a result of the optimization studies on expression, induction of expression 
was not observed at temperatures lower than 37 °C. Also inductions performed when 
the starting OD is less then 0.6, shown to not work. The optimum conditions for the 
expression of the core protein was found to be;
Temperature of induction 
Concentration of IPTG 
ODeoo at the start of induction 
Induction time
37 °C 
0.1 mM 
0.6
4 hours
Large scale induction of the core protein expression under optimum 
conditions was carried out twice in 500 ml cultures and the cells were harvested by 
centrifuging at 6000 rpm for 15 minutes at 4 °C in a Beckman Avanti J-25I 
centrifuge. The cells were then washed with 30 ml PBS and pelleted again. The 
pellets were kept at -20 °C until used for purification. Figure 3.13 shows the 
induction in these 500 ml cultures.
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The bacterial pellet of large scale induction product (from 0.5 L culture) was 
resuspended in 8 ml sonication buffer (50 mM NaP0 4  Buffer; 93% dibasic, 7% 
monobasic, 300 mM NaCl, 10% Glycerol) and sonicated on ice by sixteen 15 seconds 
bursts at full setting. Soluble and insoluble fractions were separated by centrifuging at 
18,000 rpm for 35 minutes at 4 °C in a Beckman Avanti J-25I centrifuge. The 
insoluble portion was resuspended in Buffer В containing 8 M urea and incubated by 
continuous stirring at room temperature for 1 hour and then sonicated on ice by 
sixteen 15 seconds bursts at full setting. The soluble and insoluble samples were 
separated by centrifuging at 18,000 rpm for 35 minutes at 4 °C in a Beckman Avanti 
J-25I centrifuge. 10 |il samples were taken from each step and were analyzed by SDS 
polyacrylamide gel electrophoresis (Figure 3.14). PAGE analysis clearly showed that 
the core protein was not soluble under non-denaturing conditions (lane 5) some 
portion of the protein was soluble in the presence of 8 M urea (lane 7).
3.2.6 Qiaexpress E.coli Protein Expression System
The QIAexpress purification system employs a novel metal chelate adsorbent, 
Ni-NTA resin that provides an efficient and simple one step method for rapid protein 
purification. The power of the expression system is based on the remarkable affinity 
of the Ni-NTA resin for proteins and peptides that contain six consecutive histidine 
residues - the 6xHis affinity tag- at either their N terminus or C terminus.
3.2.5 Cell Lysis and Solubilization of the Core Protein
3.2.6.1 Ni-NTA Resin
Immobilized metal chelate affinity chromatography, first used to purify 
proteins in 1975 (Parath et al., 1975), has become a widely used technique. Until the
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Figure 3.12; Small scale purification of the core protein.
Lane 1 shows the first wash and lane 2 shows 
the purified core protein in the elute.
1 2 3 4 5
Figure 3.13: Large scale induction of the core protein 
expression under optimum conditions. Lanes 
2 and 4 shows large scale expression samples. 
Lanes 3 and 5 are uninduced samples. Lane 1 
is protein size marker (Pharmacia). Expressed 
core protein bands are shown with the 
arrows.
97.5
66
45
31
21
’S ' *
1 2 3 4 5 6 7
Figure 3.14: Cell lysis and solubilization of the core 
protein.
Lanes
1- Uninduced
2- Induced for 4 hours
3- Protein size marker (Pharmacia)
4- Pellet after sonication under 
nondenaturing conditions
5- Soluble fraction after first 
sonication
6- Pellet after sonication under 
denaturing conditions
7- Soluble fraction after second 
sonication
32-
development of NT A (Nitrilo-tri-acetic acid), the chelating ligand iminodiacetic acid 
(ГОА) was charged with metal ions such as Zn '^^  and Ni^ ,^ and then used to purify a 
variety of different proteins and peptides (Sulkowski et al, 1985). However, the IDA 
ligand has only three chelating sites, and does not bind metal ions containing six 
coordination sites tightly. The weak binding allows the metal ions to be washed out 
of the resin upon loading with strong chelating proteins and peptides, or during the 
washing of the bound proteins. This results in low yields, impure products and heavy 
metal contamination of purified proteins.
NT A resin is a new chelating adsorbent developed at Hofifmann-LaRoche 
(Basel) in order to overcome these problems. The NTA ligand has four chelating sites 
which can interact with metal ions. Thus NTA occupies four of the six ligands 
binding sites in the coordination sphere of the Ni^  ^ ion, leaving two sites free to 
interact with the 6xHis tag (Figure 3.15). This allows NTA to bind the metal ions far 
more stably than other available chelating resins, retaining the ions under a wide 
variety of conditions. As a result, this resin binds 6xHis tagged proteins 1000 times 
more tightly than IDA (Hochuli et al., 1990), allowing for more discriminating 
separation of contaminating proteins. This extremely high affinity interaction between 
the 6xHis tag and Ni-NTA resin permits the purification of proteins from less than 
1% to greater than 95% homogeneity (Hochuli et al., 1990).
3.2.6.2 Protein Binding
Protein containing one or more 6xHis affinity tags, located at either the amino 
or carboxyl terminus of the protein, bind to the Ni-NTA resin with an affinity 
(Kd=10'^, pH 8.0) for greater than the affinity between most antibodies and antigens, 
or enzymes and substrates. This means that any host proteins that bind non-
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specifically to the NT A resin can easily be washed away under relatively stringent 
conditions, without effecting the binding of the 6xiiis tagged proteins. Zinc finger 
proteins for example, will bind to the Ni-NTA resin, but can easily be discriminated 
from the proteins carrying the 6xHis tag, which bind more tightly. The high binding 
constant also allows proteins in very dilute solution, such as does expressed at low 
levels or secreted into the media, to be efficiently bound to the resin.
The binding of tagged proteins to the resin does not require any functional 
protein structure and is thus unaffected by strong dénaturants such as 6 M guanidine 
hydrochloride or 8 M urea. This means that, unlike purification systems which rely on 
antigen/antibody or enzyme/substrate reactions, Ni-NTA can be used to purify almost 
any protein, even those that are insoluble under non-denaturing conditions.
The stability of the 6xHis/Ni-NTA interaction in the presence of low levels of 
P-mercaptoethanol (1-10 mM) prevents the co-purification of host proteins that may 
have formed disulfide bonds with the protein of interest during cell lysis.
The presence of detergents such as Triton X-100 and Tween 20 (0.1-1%), or 
high salt concentrations (0.1-1 M), has also no effect on protein binding. This 
facilitates the complete removal of proteins that would normally co-purify due to 
various non-specific interactions. Nucleic acids that might associate with certain 
DNA and RNA binding proteins can also be efficiently removed without affecting the 
recovery of the tagged protein.
3.2.6.3 Protein Elution
Elution of the tagged proteins from the column can be achieved by several 
methods. Reducing the pH will cause the histidine residues to become protonated, 
and to dissociate from the Ni-NTA. Monomers are generally eluted at approximately
9^1
Figure 3.15: Interaction of ion with NTA resin and 
histidine tag
N H ^ - C H -  c o p '
CH1
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Figure 3.16: Chemical structure of imidazole and histidine
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pH 5.9 while aggregates and proteins that contain more than one 6xHis tag elute 
around pH 4.5.
Elution can also be achieved by competition with imidazole (Figure 3.16), 
which binds to the Ni-NTA and displaces the tagged protein. Low levels of imidazole 
can also be used to selectively elute contaminants that bind less strongly to the resin 
(Hochuli et al., 1990).
3.2.6.4 Binding Capacity
The Ni-NTA resin is composed of a high surface concentration of NTA ligand 
attached to Sepharose CL-6B, sufficient for the binding of approximately 5-10 mg of 
6xHis tagged protein per ml of resin. Ni-NTA resin can be reused 3-5 times for 
purification of the same protein and is very stable.
3.2.6.5 6xHis Tag
The affinity tag that binds to the Ni-NTA resin consists of just six consecutive 
histidine residues. Its small size means that there is minimal addition of extra amino 
acids to the recombinant protein. It is non-immunogenic, or at most very poorly 
immunogenic, in all species except some monkeys. It is uncharged at physiological 
pH and generally does not affect the secretion, compartmentalization, or folding of 
the protein to which it is attached.
3.6.2.3 Purification of Core Protein Under Non-Denaturing Conditions
Although the amount of the core protein solubilized under native conditions 
was very small, this soluble portion was loaded on a Ni-NTA resin in order to purify 
under non-denaturing conditions. All purification steps under non-denaturing
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conditions were carried out in cold room and also 0.1 to 0.2 mM PMSF was added at 
each 2 hours interval in order to inactivate the proteases.
The Ni-NTA resin was kept as 50% slurry in 20% ethanol solution at 4°C for 
long term storage. 8 ml resin slurry was equilibrated with the sonication buffer, 
before incubating with the solubilized protein mixture by continuous stirring for 1 
hour at 4 °C. Column was made from 5 ml syringes plugged with glass cotton. The 
resin-protein mixture was slowly loaded to the column and the flowthrough was 
collected in a labeled tube for further analysis. After the resin was settled and all the 
unbound protein solution drained out the resin was washed with 20 ml Buffer C 
containing 1 mM imidazole to decrease nonspecific interactions. Step elution with 
Buffer C containing the following concentrations of imidazole and the elutes were 
collected in 1.7 ml microcentrifuge tubes labeled from 1 to 60;
Table 3.3: Elution steps in native purification of core protein.
Imidazole Concentration 
(mM)
Volume Used 
(ml)
Elutes collected
2 10 1-6
4 10 7-12
8 10 13-18
16 10 19-24
32 10 25-30
64 10 33-36
128 10 37-42
256 10 43-48
400 10 49-54
500 20 55-60
The column was then washed with 20 ml Buffer C containing 1 M imidazole 
to strip down the remaining proteins in the column.
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The purity and the protein content of the elutes were checked by SDS-PAGE. 
As the elutes were containing imidazole they were incubated at 37 °C for 10 minutes 
after adding loading buffer in order to avoid imidazole mediated cleavage of labile 
bonds. At the end of native purification no bands were observed on the SDS-PAGE 
representing the purified core protein.
3.6.2.4 Purification of Core Protein Under Denaturing Conditions
Purification was carried out in similar manner for both native and denaturing 
conditions however all the buffers used during the sonication and the purification had 
contained 8 M urea and all steps of purification was carried out at room temperature 
in order to avoid precipitation of the urea.
Eight milliliters of resin slurry was equilibrated by incubating with Buffer B 
containing 8 M urea for 30 minutes, before incubating with the solubilized protein 
mixture by continuous stirring for 1 hour at room temperature. Column was made 
from 5 ml syringes plugged with glass cotton as in the case of native purification. The 
resin-protein mixture was slowly loaded to the column and the flow through was 
collected in a labeled tube for further analysis. After the resin was settled and all the 
unbound protein solution drained out the resin was washed with 20 ml Buffer C 
containing 8 M urea. Step elution with Buffer C containing 8 M urea and the 
tabulated concentrations of imidazole was carried out and the elutes were collected in
1.7 ml microcentrifuge tubes labeled from 1 to 48;
The column was then washed with 20 ml Buffer C containing 8 M urea and 1 
M imidazole to strip down the remaining proteins in the column.
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Table 3.4: Elution steps 
conditions.
in first purification of core protein under denaturing
Imidazole Concentration 
(mM)
Volume Used 
(ml)
Elutes collected
10 10 1-6
20 10 7-12
40 10 13-18
80 10 19-24
160 10 25-30
250 10 33-36
400 10 37-42
500 10 43-48
Purification under denaturing conditions were carried out for two times. The 
purity and the protein content of the elutes were checked by SDS-PAGE, Figure 3,17 
shows the elution steps. Core protein was seen to be eluted between 160 mM and 
250 mM imidazole steps. As a result during the second purification under denaturing 
conditions the following elution steps were applied.
Table 3.5: Elution steps in second purification of core protein under denaturing 
conditions.
Imidazole Concentration Volume Used Elutes collected
(mM) (ml)
80 20 1-12
160 10 13-18
250 10 19-24
500 20 25-36
Figure 3.17: SDS-PAGE analysis of first purification samples
Elutes: 1 3 5 7 9 11 13 15 16 17 18 19 20 M 22 23 24 25 26 27 28
Figure 3.18: SDS-PAGE analysis of second purification samples
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Figure 3.18 shows the purification products. The core protein was eluted 
mostly between IS*** and I?* elutes.
3.2.1 Concentration and Renaturing of the Core Protein
For the first purification products purified core protein band was detected in 
elutes 26 to 34 with varying intensities, so these elutes were collected in two 
fractions;
fraction 1; 32,33
fraction 2; 26,27,28,29,30,31,34
These purified protein fractions were renatured by dialyzing against PBS 
containing 0.1% Tween 20 to remove urea from the protein mixture as described 
before and the dialysis bag was then treated with aquasid to remove excess water 
from the mixture and to concentrate the protein. The concentrated protein was again 
dialyzed against 55% glycerol in PBS containing 0.1% Tween 20, to further 
concentrate the protein and to enable storage at -20 °C.
The elutes from the second purification were collected in three fractions; 
fraction 1; 7-13 
fraction 2; 16-22 
fraction 3; 23-31
and were renatured and concentrated as described before. Elutes 14 and 15 were kept 
denatured and stored at 4 °C.
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Protein concentration was determined by Bradford (1976) method by using 
the BioRad protein assay kit. A standard curve was plotted by using bovine serum 
albumin (BSA) at known concentrations as tabulated below.
Table 3.6: Preparation of the standard curve for Bradford protein quantification 
assay,
3.2.1 Quantification of the Purified Core Protein
pg BSA/ml Volume of Bradford Dye (pi) Volume of ddH20 (pi)
0 (Blank) 200 800
1.34 200 799
2.68 200 798
4.02 200 797
5,36 200 796
6.70 200 795
8.04 200 794
The standard curve was fitted to a linear equation,
ODs95== 0.0739 [ Core Protein ({xg/p.!)] + 0,4659
Fraction 1 (600 pi) and Fraction 2 (800 pi) from the first purification were 
calculated to have 0.450pg/pl and 0.170 pg/ml core protein respectively. The 
denatured fraction of the second purification (elutes 14 and 15, 3 ml) was calculated 
to contain 0.200 pg/pl core protein. These three fractions contained a total of 1 mg 
core protein, which was sufficient to carry out the further experiments.
3.3 IMMUNODETECTION OF ANTIBODIES AGAINST HCV CORE 
PROTEIN
3.3.1 Antigens for the Diagnosis of Hepatitis C Virus Infection
The first generation assays developed for the detection of anti-HCV 
antibodies in the sera of the patients contained an antigen called C l00-3 which was
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deduced from the junction point of the non-structural proteins 3 and 4 (NS3 and 
NS4) of the prototype HCV (la) strain (Kuo et al., 1989), However, C l00-3 
antibody (anti-C 100-3) was not detected in all post transfusion NANBH cases, 
probably because of the delayed response to Cl 00-3 antigens as it was encoded in the 
non-structural part of the HCV or the existence of different genotypes of HCV 
(Chiba et al., 1991). Currently second and third generation en2yme immunoassays for 
anti-HCV detection are the most practical screening tests for the diagnosis of HCV 
infection in the world. They contain antigens from the core region as well as the 
antigens from NS3, NS4 and NS5 regions.
Core protein is the most highly conserved region of the hepatitis C virus open 
reading frame and it is shown to be highly immunogenic. The core antigens 
commercially used today are either fused with a larger protein such as super oxide 
dismutase (SOD) or only a small portion of it from the N terminus is (2-50 amino 
acids) is cloned. Figure 3.19 schematically shows the core antigens found in two of 
the commercially used diagnostic kits. Several studies have been made on usage of 
core antigen in the diagnosis of hepatitis C (Chiba et al., 1991; Yoshikawa et al., 
1992; Seki et al., 1995) and it has been found useful for the early diagnosis of the 
disease. The antigens used in these studies were either partially purified or shorter 
then the novel core protein.
The core antigen produced at the end of this study contains the amino acids 1 
to 178 of the HCV polyprotein and only a veiy short strip of six histidines was added 
in order to enable purification. Nine other amino acids coming from the multiple 
cloning site are also present (Figure 3.20).
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EIA-3 RIBA-3
CORE 119
GORE 150
Figure 3.19: Core antigens present in third generation commercial kits
MRGS CORE 178
■ :k ,·
Total 193 amino acids 
Expected Size 22kDa
. .-
"-vSij|KLN
Figure 3.20: Schematic presentation of core antigen expressed and 
purified in this study
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Western blotting with the core protein was carried out in order to detect 
antibody responses against core antigen. For the transfer to the membrane and the 
immunological detection of the antibodies the methods described before in section
2.2.11 was used. 1.2 p,g of the core antigen was loaded to each well in order to 
detect any immunological response against the core protein.
First Western blotting was carried out with the small scale purification 
product of the core protein and the first antibody was the sera of the patient 8, whose 
serum had been used to clone the core region. The serum of the patient 8 was diluted 
100 times. The primary antibodies were detected by AP conjugated secondary 
antibodies against IgG, IgM and IgA. Figure 3.21 shows the result of this blot. The 
core protein immobilized on the membrane gave a strong reaction with the antibodies 
in the serum of patient 8.
The purified fraction 1 and 2 of the first purification was used again for 
Western blotting by using the sera of patients 46, 34 and 35. Also a negative control 
(EN) serum, which is known to be HCV RNA negative, was also used as the primary 
antibody in order to see whether core protein gave any unspecific reactions with 
human sera. The blots are shown in Figure 3.22. Core protein did not give any 
significant reaction with the negative controls’ sera, however gave strong reaction 
with all three patients’ sera.
In order to show that this reaction of core antigen with the patients’ sera was 
not due to the presence of the 6xHis tag, also 1.2p.g/well of another histidine tagged 
protein pl6 (cyclin dependent kinase inhibitor) was loaded as well as the core protein 
and blotted by using the patient 34’s sera as the first antibody. Figure 3.23 shows this
3.3.2 Immunological Detection of Immobilized Core Protein (Western Blotting)
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Figure 3.21: Western blotting of the purified core protein 
by using patient 8’s sera as the first antibody.
1 2 3 1 2 3  1 2 3  1 2 3
Figure 3.22: Western Blotting of the core protein with 
serum samples. Negative control EN, and 
patients 34, 35, 46. In each blot lane 1 
contains M l5 lysate, lanes 2 and 3 contain 
purified core protein.
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Figure 3.23; Western blotting of core protein and histidine 
tagged pl6 with patient 34’s serum.
Lanes
1 -  p l 6
2 -  p l 6
3- Protein size marker (Pharmacia)
4- HCV core protein
5- HCV core protein
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blot. Although there was a strong reaction against core protein, patient 34 show no 
reaction against the histidine tagged p i6.
3.3.3 Indirect Enzyme-Linked Immunosorbent Assay (ELISA) to Detect
Hepatitis C Virus Core Protein Specific Antibodies in Human Sera
In order to detect antibodies against antigens, ELISA is the most efficient 
easy and quick method. Around 100 serum samples were tested by using core antigen 
coated onto ELISA plates. 36 of these serum samples were coming from Çukurova 
University Hospital Gastroentrology Department, Adana, Turkey, from the chronic 
hepatitis C patients, which have been tested with third generation enzyme 
immunoassays (EIAs) and found to be Anti-HCV positive. Rest of the serum samples 
were negative control samples who have been tested in Numune Hospital, Ankara, 
Turkey, and found to be Anti-HCV, Anti-HBV and Anti-HIV negative.
As the antigen 100 ng of core protein was coated per well of the 96 well 
micro titer plate and ELISA test was performed as described in section 2.2.12. Each 
serum sample was studied in two wells and their average was taken for evaluation of 
the results.
Tables 3.7 and 3.8 gives the readings of these ELISA tests, and Appendix D
illustrates their evaluation by giving a sample calculation. Whether the result of
ELISA was positive or not was determined by comparing the optical density of the
sample with the optical density of the negative control on the same plate. The
negative control sample was previously tested and found to be HCVRNA negative by
reverse transcription PCR and anti-HCVCORE negative by Western blotting. The
samples with ELISA readings 2.5 fold or more than that of the negative control were
accepted to be positive for the Anti HCVCORE, and samples which had ELISA
readings 1.5 fold or less than that of the negative control were accepted to be
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negative. No ELISA readings were detected between 1.5 and 2.5 fold of the negative 
control. As core protein was produced in E.coli, some bacterial impurities might have 
remained in the core protein and might have reacted with human sera which might 
have cause false positive results. In order to see if these subjects were reactive 
against Ml 5 proteins or not, ELISA of each sample with 100 ng/well of Ml 5 lysate 
was also made and this was referred during decision for the positivity of the sample 
when needed. Figures 3.24 to 3.28 show the results of the ELISA tests on graphics.
As a result of the ELISA tests, 6 of the 36 chronic hepatitis C patient were 
found to be negative for Anti-HCVCORE where all the others were positive. From 
the 60 anti HCV negative control samples non of them found to be positive, all found 
to be negative at the end of the ELISA tests.
Patients 2, 19, 20, 42, 43 and 45 were found to be negative for Anti- 
HCVCORE antibody at the end of the ELISA tests. In order to decide whether these 
negative results were due to in sensitivity of ELISA or lack of the anti HCVCORE 
antibody. Western blotting was performed for the samples 2, 19, 20 and 45 (there 
was not enough serum of patients 42 and 43 for Western blotting). As negative 
control, the serum EN, which had been used during the previous western blots and 
ELISA tests, was used. As positive control, patients’ samples 26 and 46 were used. 
Also from negative control serum samples which were also shown to be negative by 
the ELISA tests, 4, 11 and 21 were used in order to show lack of any reaction with 
the core antigen. In these western blots horse radish peroxidase conjugated anti 
human antibody and ECL kit was used in detection of the antibodies against core 
antigen, as this is the most sensitive method to detect any reaction against an antigen. 
Figure 3.29 shows the results of these blots. These Western blots have shown that
patients
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Figure 3.29: Western blotting for confirmation of the negative 
results in ELISA among patients’ samples. M, 
protein size marker; EN, negative control serum; 
Patient 26, positive control for western blotting; and 
patients 2, 19, 20, 45.
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19, 20, and 45 were lacking any anti-HCV core antibody however patient 2 has been 
shown to contain the anti-HCV core antigen.
The HCV RNA status of the patient samples were determined by performing 
the RT-PCR of the 5’UTR by E.Yildiz in our lab. The HCV RNA status of the 
patient samples are given on Table 3.7.
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Table 3.7: ELISA Results for the Chronic Hepatitis C Patients’ Samples
Patient No ELISA Reading
ELISA Reading 
of the Negative 
Control 
(on the same 
plate)
Relative Value 
of ELISA Result of ELISA HCV RNA 
status
15 0,401 0,088 4,6 + +
20 0,096 0,088 1,1 - -
23 0,373 0,088 4,3 +
24 0,309 0,088 3,5 + +
26 0,608 0,088 6,9 +
28 0,454 0,088 5,2 -f +
29 0,456 0,088 5,2 +
30 0,438 0,088 5,0 + -f
32 0,254 0,088 2,9 + +
33 0,426 0,088 4,9 +
35 0,323 0,088 3,7 + +
36 0,367 0,088 4,2 + +
37 0,337 0,088 3,8 -l· +
38 0,371 0,088 4,2 + +
39 0,582 0,088 6,6 + -f
42 0,121 0,088 1,4 - -
44 0,313 0,088 3,6 + -f
2 0,227 0,147 1,5 - +
7 0,532 0,147 3,6 +
16 0,434 0,147 2,9 + +
17 0,619 0,147 4,2 + +
18 0,844 0,147 5,7 + +
19 0,136 0,147 0,9 - -
25 0,547 0,147 3,7 + +
27 0,497 0,147 3,4 + +
31 0,474 0,147 3,2 + 4-
34 0,485 · 0,147 3,3 + +
40 0,614 0,147 4,2 + +
43 0,165 0,147 1,1 - -
44 0,470 0,147 3,2 + +
45 0,141 0,147 1,0 - -
46 0,804 0,147 5,5 + +
48 0,376 0,147 2,6 + -f
49 0,441 0,147 3,0 + +
50 0,952 0,147 6,5 + +
55 0,509 0,147 3,5 4-
II7
Table 3.8: ELISA Results for the Anti HCV, Anti HBV and Anti HIV Negative 
Samples
Sample No ELISA Reading
ELISA Reading of 
the Negative 
Control (on the 
same plate)
Relative Value of 
ELISA
Result of ELISA
4 0,189 0,173 1,1 -
5 0,169 0,173 1,0 -
6 0,236 0,173 1,4 -
7 0,225 0,173 1,3 -
8 0,210 0,173 1,2 -
9 0,154 0,173 0,9 -
10 0,149 0,173 0,9 -
11 0,161 0,173 0,9 -
13 0,159 0,173 0,9 -
14 0,151 0,173 0,9 -
15 0,153 0,173 0,9 -
16 0,170 0,173 1,0 -
18 0,121 0,173 0,7 -
19 0,152 0,173 0,9 -
20 0,143 0,173 0,8 -
21 0,146 0,173 0,8 -
22 0,188 0,173 1,1 -
23 0,159 0,173 0,9 -
24 0,148 0,173 0,9 -
27 0,212 0,173 1,2 -
28 0,179 0,173 1,0 -
29 0,228 0,251 0,9 -
30 0,172 0,251 0,7 -
31 0,374 0,251 1,5 -
32 0,190 0,251 0,8 -
33 0,165 0,251 0,7 -
34 0,213 0,251 0,8 -
35 0,302 0,251 1,2 -
36 0,286 0,251 1,1 -
37 0,178 0,251 0,7 -
38 0,150 0,251 0,6 -
39 0,224 0,251 0,9 -
40 0,222 0,251 0,9 -
43 0,235 0,251 0,9 -
44 0,220 0,251 0,9 -
45 1 0,242 0,251 1,0 -
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Table 3.8 (cont’d):
Sample No ELISA Reading
ELISA Reading of 
the Negative 
Control (on the 
same plate)
Relative Value of 
ELISA
Result of ELISA
46 0,222 0,251 0,9 -
47 0,172 0,251 0,7 -
48 0,177 0,251 0,7 -
49 0,164 0,251 0,7 -
50 0,135 0,251 0,5 -
51 0,168 0,251 0,7 -
52 0,151 0,182 0,8 -
53 0,164 0,182 0,9 -
54 0,173 0,182 1,0 -
55 0,126 0,182 0,7 -
56 0,136 0,182 0,7 -
58 0,198 0,182 1,1 -
59 0,169 0,182 0,9 -
60 0,220 0,182 1,2 -
62 0,154 0,182 0,8 -
63 0,167 0,182 0,9 -
64 0,139 0,182 0,8 -
65 0,182 0,182 1,0 -
67 0,174 0,182 1,0 -
69 0,152 0,182 0,8 -
70 0,134 0,182 0,7 -
71 0,127 0,182 0,7 -
72 0,155 0,182 0,9 -
96 0,167 0,182 0,9 -
98 0,186 0,182 1,0 -
105 0,209 0,182 1,1 -
106 0,192 0,182 1,1 -
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4. DISCUSSION
In this study it was aimed to clone, express and purify the core protein of the 
hepatitis C virus and to test the human sera with this viral antigen in order to asses its 
ability to diagnose hepatitis C.
Diagnosing hepatitis C virus infection is very important as hepatitis C virus 
infections is one of the major causes of chronic liver disease and liver transfusions 
world wide. Presently 1.5% of the general population in Turkey is thought to be 
infected with hepatitis C virus which corresponds to around 1 million people. In the 
coming years chronic hepatitis C caused by this virus will be a major health concern. 
As the hepatitis C virus is a blood bom vims, plasma transfusions and organ 
transplantations are the major causes of transmission of the vims. In Turkey very 
recently blood donors sera are started to be tested with enzyme immunoassays for 
detection of antibodies against hepatitis C vims antigens. This application hopefully 
will lower the transmission of disease via blood transfusions in the following years.
At the start of this study it was aimed to clone the entire core region which is 
191 amino acids long. However the sequence of the vims varies among genotypes 
and the genotype of the patient samples were not known at the start, so the primer 
set was designed in order to amplify 178 amino acids of the core protein because the 
region after nS*** amino acid shows lots of variations among isolates and to find a 
constant region to design the reverse primer was not possible. Moreover the C 
terminal end of the core protein (amino acids 172-191) is highly hydrophobic and
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shown to be cleaved in many studies from the 172"*^  amino acid so most probably the 
first 171 amino acids long region of the protein contains the mainly important 
domains and all of the immunodominant epitopes. Thus, core antigen that is 178 
amino acids long is comparable to the entire core region product, as an antigen probe 
in detecting antibodies raised by hosts against the HCV core protein. Also presence 
of the hydrophobic domains in the protein might have been toxic to the E.coli cells 
where the expression is performed. Also hydrophobic regions in the antigens can 
cause non-specific interactions with the antibodies and then may give false positive 
results in ELISA tests.
The amplified core region from a chronic hepatitis C patients serum was then
cloned into pQE30 a Type IV construct of the pQE vector family. Type IV
constructs place the 6xHis tag at the N terminus of the protein and are the most
commonly used ones and they do not require the coding sequence to bear a stop
codon in frame because they themselves contain stop codons 3’ to the polylinker
sequence in all three reading frames. Moreover, in the pQE expression vectors. Type
IV proteins are often expressed 2-4 times more efficiently then other types of pQE
constructs. Also as the N terminus of the core protein is highly basic in nature and the
C terminal is rather hydrophobic, placing the 6xHis tag at the N terminus would have
improve its exposure to the Ni-NTA resin.
pQE30 was chosen as the cloning and expression vector for this study, as the
first restriction enzyme site BamHl is in frame with the start codon. The core region
sequence from various isolates were searched by computer for the restriction enzyme
sites available at the multiple cloning site of the plasmid and no internal BamlU and
Hindlll sites were found in the core region. Therefore these two enzymes were
introduced to the ends of the core region {BamRl to the 5 ’ and Hindlll to the 3 ’ end
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of the gene) and the core region bearing these two restriction enzyme sites was 
amplified from a chronic hepatitis C patient’s (patient 8) sera by PCR. The PCR 
amplified fragment was then digested with these two enzymes as welt as the pQE30 
vector and ligated. All cloning steps were performed by using the E.coli strain JM109 
which has a mutated lad  promoter that transcribes 10 fold more lac repressor 
therefore tightly represses the protein expression during the propagation and storage 
steps. This tight repression enables the propagation of the plasmid without the 
protein expression and inhibits the selection of expression mutants during these steps.
The clone was sequenced a few times, but due to an inhibiting factor, a 100% 
clear sequence could not achieved. This was most probably because of the primers. 
The most clear sequence achieved is presented in Appendix B and comparison with 
the sequence of commercial core antigens is given in Appendix C. Our core antigen 
seems to show significant variations from the antigens of kits produced by Chiron or 
Abbot. At the start the genotype of the virus from which the core region cloned from 
was not known, but later the 5’UTR of the virus from patient 8 was amplified and 
genotyped by E. Yildiz in Molecular Biology and Genetic Department, Bilkent 
University and found to be lb. This seems to be advantageous to have a core antigen 
in subtype lb for Turkish population, as there are some unconfirmed data mentioned 
in a couple of articles stating that the HCV lb subtype is the most common among 
Turkish population (Simmonds et al., 1995).
After cloning of the core region into pQE30 vector, core protein was
expressed in Ml 5 host cells and the expression was shown and optimized with a
series of small scale inductions. The protein was expressed in high levels and thought
to be soluble as the size of the protein was small and most of the hydrophobic region
of the protein was excluded. However after various attempts to solubilize the protein
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under native conditions it was shown that almost all of the protein remained within 
the insoluble portion. It seems that the speed of protein folding could not keep up 
with the rate of translation and as a result inclusion bodies were formed. The protein 
was then solubilized under denaturing conditions in buffers containing 8 M urea. By 
this way almost 50-60% of the expressed protein was extracted from the pellet after 
first treatment, however still a considerable amount was left in the insoluble fraction. 
The proteins expressed in Type IV constructs such as pQE30 contain their 
6xHistidine tags at their N terminus. This tag should not be hid by the other parts of 
the protein as it should interact with the Ni^  ^ ions of the Ni-NTA resin. Thereby 
dénaturation of the protein enhances this interaction as the histidine tag is more 
exposed to the Ni^  ^ions.
The solubilized portion of the core protein was purified by using Ni-NTA 
resin (Qiagen) as the Ni^  ^ ion adsorbent and more than I mg of the core antigen was 
purified under denaturing conditions. The 6xHis affinity tag that binds to the Ni-NTA 
resin consists of just sbc consecutive histidine residues. Its small size enabled minimal 
addition of extra amino acids to the core protein. To date, although many antibody 
assay systems are commercially available, all of them use fusion polypeptides or 
synthetic oligopeptides for the HCV core antigen. However fusion polypeptides 
might exhibit non specific reactions to the fusion partner and synthetic oligopeptides 
might reduce the sensitivity by limiting the antigenic epitope. In this study the core 
antigen expressed contained almost all the possible immunodominant epitopes and 
the 6xHis tag at the N terminus was a very short sequence addition. 6xHis tag is 
mostly non-immunogenic, and it was also shown that a patient’s (patient 34) sera did 
not give any reaction against another 6xHis tagged protein pl6 while it was giving a
strong reaction with the purified core protein.
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There are first, second and third generation assays found world wide for the 
diagnosis of the hepatitis C virus infection. The first generation assays developed for 
the detection of anti-HCV antibodies in the sera of the patients contained an antigen 
called C l00-3 which was deduced from the junction point of the non-structural 
proteins 3 and 4 (NS3 and NS4) of the prototype HCV (la) strain (Kuo et al., 1989). 
However, C l00-3 antibody (anti-C 100-3) was not detected in ail post transfusion 
NANBH cases, probably because of the delayed response to C l00-3 antigens as it 
was encoded in the non-structural part of the HCV or the existence of different 
genotypes of HCV (Chiba et al., 1991). Currently second and third generation 
enzyme immunoassays for anti-HCV detection are the most practical screening tests 
for the diagnosis of HCV infection in the world. They contain antigens from the core 
region as well as the antigens from NS3, NS4 and NS5 regions.
Core protein is the most highly conserved region of the hepatitis C virus open 
reading frame and it is shown to be highly immunogenic. Also, as the core protein is 
the putative capsid protein of the hepatitis C virus and antibodies directed to the viral 
capsid proteins are expected to arise early in infection, antibodies against core antigen 
is most probably arise much earlier than the antibodies against nonstructural proteins. 
Thus the antibodies against the core antigen is expected to have a narrow window 
period between the infection and the serological diagnosis. Therefore the presence of 
the core antigen in a serological diagnosis system enhances its ability for early 
diagnosis. Also previously it has been shown that the appearance of the anti-HCV 
core antibodies in the sera correlated with the increase in the ALT levels (Chiba et al., 
1991), thus appearance of the anti HCV core antibody might also be useful in 
detection of the liver injury.
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Core protein was previously expressed in insect cells (Chiba et al., 1991; 
Lanford et al., 1993), mammalian cells (Harada et al., 1991), yeast (Chien et al., 
1992) and in E.coli (Muraiso et al., 1990; Nasoff et al., 1991; Mita et al., 1992; Mori 
et al., 1992; Takahashi et al., 1992; Yokosuka et al., 1993; Seki et al., 1995) and 
have been found useful for early diagnosis, blood donor screening and the diagnosis 
of hepatitis C (Chiba et al., 1991; Nasoff et al., 1991; Hosein et al., 1991). However, 
either the expressed core antigens were not purified to the extent of core antigen in 
this study or they were not covering as large as 178 amino acids portion of the core 
protein.
The core antigen purified was then used in establishment of an ELISA system 
for the detection of antibodies against HCV core protein in human sera. Around 100 
serum samples were tested by using core antigen coated onto ELISA plates. 36 of 
these serum samples were coming from Çukurova University Hospital 
Gastroentrology Department, Adana, Turkey, taken from the chronic hepatitis C 
patients. These serum samples have been tested with third generation enzyme 
immunoassays (EIA III) in Çukurova University Hospital and found to be Anti-HCV 
third generation positive. Rest of the serum samples were negative control samples 
who have been tested' in Numune Hospital, Ankara, Turkey, and found to be Anti- 
HCV, Anti-HBV and Anti-HIV negative.
At the end of the ELISA tests the cut off value for the positive results were
found to be the 2.5 fold of the average of the negative control readings. The limit for
the negative results were found to be the 1.5 fold of the negative control. There were
no ELISA readings between these two limits, however in the future, the ELISA of
the sample having an ELISA reading between these values should be retested and if
this repeatedly happens another method such as Western blotting should be used in
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determining the presence or absence of the anti-HCV antibody in the patients sera. 
As a result of the ELISA tests, 6 of the 36 chronic hepatitis C patient were found to 
be negative for Anti-HCVCORE where all the others were positive. From the 60 anti 
HCV negative control samples non of them found to be positive, all found to be 
negative at the end of the ELISA tests.
Patients 2, 19, 20, 42, 43 and 45 were found to be negative for Anti- 
HCVCORE antibody at the end of the ELISA tests. In order to decide whether these 
negative results were due to insensitivity of ELISA or lack of the anti HCVCORE 
antibody. Western blotting was performed for the samples 2, 19, 20 and 45. At the 
end it was shown that patients 19, 20, and 45 were lacking any anti-HCV core 
antibody however patient 2 has been shown to contain the anti-HCV core antigen 
which was most probably missed by the ELISA test. Also the patient 2’s sera has 
given an ELISA reading which was 1.5 fold of the negative result which is right at 
the limit of the negative results, so it might be concluded that the results at the limits 
might be retested to confirm, before concluding on a final decision.
At the end of the ELISA tests 86% of the patients’ samples were shown to
contain antibodies against HCV core antigen with ELISA test which is in
concordance with the results of the previous studies (Chiba et al., 1991; Yoshikawa
et al., 1992; Seki et al., 1995). The negative results among patient samples (except
patient 2) were most probably due to lack of anti HCV CORE antibodies in the sera
of the patients. Five of the anti-HCV core negative patients which are positive in the
third generation EIAs seemed to either contain antibodies against the other antigens
in this assay such as antigens from NS3, NS4 and NS5 regions or they are false
positive results due to the third generation assay. The HCV RNA status of these
samples suggests that they are most probably false positive results of the third
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generation assay however this should be confirmed by repeating the HCV RNA 
detection.
The core antigen showed no false positive results among the negative control 
samples which showed that the purified antigen has made only specific interactions 
with the antibodies.
As a conclusion, in this study the core protein of the hepatitis C virus was 
cloned, expressed and purified in order to test the human sera with this viral antigen 
and it was shown that 86% of the patients with hepatitis C was diagnosed by 
detecting antibodies against this core antigen. The first generation assay was 
detecting antibodies against antigen C-100-3 in 75% of the HCV RNA positive 
patient samples, and the third generation EIAs have the ability to detect antibodies 
against HCV proteins in up to 97% of the HCV RNA positive serum sample. Our 
core antigens’ detection capacity is in between these two assays.
In future, in order to increase the detection power of the ELISA test 
established here at least one more antigen preferably from the conserved regions of 
the NS3 or NS5 proteins must be added to the assay. Also there are many studies on 
core protein about its role in viral capsid formation and modulation of the hosts 
immune system by interacting with the tumor necrosis factor receptors. Such 
functional studies might be carried out with the cloned core protein.
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Alignment of core region nucleotide sequences of various isolates belonging 
to different genotypes and subtypes.
APPENDIX A
10 20 30
■k
40* 50* 60
HCV lb D00832 ATGAGCACGAATCCTAAACCTCAAAGA?\AAACCAAACGTAACACCAACCGCCGCCCACAG
HCV la M62321 ___
HCV 2a 000944 ___....A. . .
HCV 2b 010988 ___....A. . . ,
HCV 3a 014307 . . . ....ACT. , ..A.A.... . . . . T. ,. . T . . .
HCV 3b 011443 ___
HCV 4a Y11604 ___
....ACT. . ..T...
AT.
HCV 5a Y13184 ___
HCV 6a L38339 ___----ACT. ., .A. . .
70 80
★
90* 100* 110 120
HCV lb D00832 GACGTCAAGTTCCCGGGCGGTGGTCAGATCGTTGGTGGAGTTTACCTGTTGCCGCGCAGG
HCV la M62321 ................ T..C........................ T.............
HCV 2a D00944 ....T.... T....... C..C...........C.... A. . .T.............
HCV 2b D10988 ....T.......... T. .C..............C ........ T..C..........
HCV 3a D14307 ....T.......... T. .C. .A.................A. . .G.............
HCV 3b D11443 A ___T..............C..A.................A. .TG. .C...... T...
HCV 4a Y11604 ....T.......... T.... C ...........C........ T..............
HCV 5a Y13184 ............................................. T.............
HCV 6a L38339 ................ T..C..............C........ T..............
130 140 150 160 170 180* * ·*■ ★ * *
HCV lb D00832 GGCCCCAGGTTGGGTGTGCGCGCGACTAGGAAGACTTCCGAGCGGTCGCAACCTCGTGGA
HCV la M62321 ....T. .A____
HCV 2a D00944
HCV 2b D10988
HCV 3a D14307 - .T. .A. , .G. .C. . .
HCV 3b D11443 ....AC.A.... . .AGTAC.T..... .CAA.
HCV 4a Y11604 ....... A .... .....C....... . .G. ,
HCV 5a Y13184 ....T.AA....
HCV 6a L38339 ..... C...... ____G. .A..... .A. .C. .G. .CA..A. .T
190 200 210 220 230 240* k ★ * * *
HCV
HCV
lb
la
D00832
M62321
TGGCGACAACCTATCCCCAAGGCTCGCCGACCCGAGGGCAGGGCCTGGGCTCAGCCCGGG
a. A. . T .  .G......................................... ......... T .  -G............a ................
HCV 2a D00944 A. . . .G., .C. .T. . . .A. ..G,..CT.,.ACT. . . .AAT___ ..GAA.A. .A. .A
HCV 2b D10988 C.A. .C. .G. .C. .G. .A.A. ..G...CT.,.ACC. . . .A.T___ ..GAA... .A. .A
HCV 3a D14307 C.A. .T. . .
HCV m  1 CA T r T. . - -Tra- a . ..C..T....
HCV Aa VI1fiOA A. A r ...,G. .T, .A. . .T___ . . .A. .A. .A. .A
HCV 5a Y13184 C. . . ■ AC. .
HCV 6a L38339 A. . . .G. .C. .A. .A. ___G. .AGA. .
250
*·
260★ 270★ 280* 290★ 300*
HCV
HCV
HCV
lb
la
2a
D00832
M62321
D00944
TACCCTTGGCCCCTCTATGGCAATGAGGGCTTGGGGTGGGCAGGATGGCTCCTGTCACCC 
...............................GC....... G............. T. . .
HCV 2b D10988 . .T.
HCV 3a D14307 ........ C. .A
HCV 3b D11443 .C.. ,G. . ..GT.
HCV 4a Y11604 . .T.
HCV 5a Y13184
HCV 6a L38339 . .T. , . .T. .T. .A. ...GC.
310 320 330 340 350 360
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НСѴ 1Ь D00832 CGCGGCTCCCGGCCTAGTTGGGGCCCCACGGACCCCCGGCGTAGGTCGCGTAACTTGGGT
НСѴ Іа М62321 ..Т.... Т....... С ...........А ....................С..Т.....
НСѴ 2а D00944 . .А. .Т.... Т. .СТС...........АТ......... А ..... С. .С. . .G....
НСѴ 2Ь D10988 .... G..T..T--- С............С..........А. . . А. . А. . С. . Т.... С
НСѴ За D14307 .......... Т. .АТС........ А.АС.......... АС___ С..С..T.....
НСѴ ЗЬ D11443 ..Т..Т..Т..С............. А.АТ............. А. .С. .С.... Т. . .
НСѴ 4а Y11604 . .Т.... T..A..GTC........ А.АТ..Т.... CG.G.... С..С..T .....
НСѴ 5а Y13184 . .АА---Т ...... А .......... АТ.......... G.AA. .С.СС. .Т.....
НСѴ 6а L38339 ............. АСА.......... АТ.......... С.А. .C..G..T......
370 380
*
390 400 410 420
*
НСѴ 1Ь D00832 AAGGTCATCGATACCCTTACATGCGGCTTCGCCGATCTCATGGGGTATATTCCGCTCGTC
НСѴ Іа М62321 ................... G ..............С .......... С. .А........
НСѴ 2а D00944 ................ А..G....... Т.... С .......... C..C..TG___ А
НСѴ 2Ь D10988 .GA........... А ___ G..T..T..T.... С...........C..C..TG___ Т
НСѴ За D14307 ..А................ G.... А ....... С .......... С. .С........
НСѴ ЗЬ D11443 ................ А. .G..T..A....... С .......... С ...........
НСѴ 4а Y11604 ................ А. .С..............С....... А. .С..С....... А
НСѴ 5а Y13184 .G...... С ...... А. .G.... А. ..С..С.С.......... С..С....... А
НСѴ 6а L38339 ................ А. .G..T..G....................С .... CG___ G
430★ 440★ 450* 460* 470★ 480★
НСѴ 1Ь D00832 GGCGCCCCCCTAGGGGGCGCTGCCAGGGCCTTGGCACACGGTGTCCGGGTTCTGGAGGAC
НСѴ Іа М62321 ....... Т..Т. .A. . . .-C... .G. .T. .c. . .A. . .
НСѴ 2а D00944 ....... G..С. .C. . ..TC. .A. .TC.C. .G. .T. .c. .GA.A-. .C.
НСѴ 2Ь D10988 ....... GG.T. .A. . ..TC. .A. .TC... .TA. . ,. .C.
НСѴ За D14307 ....Т.. .G. . . .A. . ..TC. .A. .A. ..c.c. .G. .T. .c. .GA...-CC. ,.T.. .A. . .
НСѴ ЗЬ D11443
НСѴ 4а Y11604 .........G.G. .TA. ..TC. .. c . .. .T. . .A. . .C.T.
НСѴ 5а Y13184 ___G___ G.T. .TCT .A. . . ..TC.C. . . .. . .. . ..GAA. . .T.
НСѴ 6а L38339 .... G..TT.G. .C. . ..TC. .GGCT. .G..c. .T. .GA. . .,CA. .C.
490★ 500★ 510★ 520★ 530 540*
НСѴ lb D00832 GGCGTGAACTATGCAACAGGGAACTTGCCCGGTTGCTCTTTCTCTATCTTCCTCTTGGCT
HCV la M62321 ........ TC... .c
HCV 2a D00944
HCV 2b D10988 . .GA.A. .T..C.. ,........ T. .A. ·»··■« to.... .T. . .....TT.GC.T. . .
HCV 3a D14307 . .GA.A. .T.TC..,............. ...... .. .c. .T. . ........TC.T. . .
HCV 3b D11443
HCV 4a Yİ1604 . .GA.C .T............. TC.C. .. .c. .T. . , .A
HCV
JLJU«A· Wn·
5a Y13184 .A
НСѴ ба L38339 .GA.С. .Т. .С.......... ТА.ТА.
550 560 570* * ★
HCV Ib D00832 TTGCTGTCCTGTTTGACCATCCCAGCTTCCGCT
HCV la M62321 C___C.
HCV 2a D00944 C..... .  .  . .CA.C---C. . .G.TC.....
HCV 2b D10988 C.T___ .A. .CG.C..AG.G. .  .  . TG..T..A
HCV 3a D14307 c ..T.C. .  .  . .C..A.T.CAT. .AG.TAGC
HCV 3b D11443 C.CT.C. .  .  . .C.... TTG. .
HCV 4a Y11604 C.T..T. ___G. .C
HCV 5a Y13184 C.T..T. ...... A
HCV 6a L38339 C.A. .c. .G. .CC.C..A.CG. .  .  . .C..G...
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Alignment of nucleotide sequence of our core protein with some of the lb 
isolates. Genebank entries of these isolates are given.
APPENDIX B:
PQE30CORE--------------------- caaagaaaaajcaaacgtaacaccaaccgccgccca||gga§gt
D50480 atgagcacgaatcctaaacctcaaagaaaaaccaaacgtaacaccaaccgccgcccacaggacgt 
D50481 atgagcacgaatcctaaacctcaaagaaaaaccaaacgtaacaccaaccgccgcccacaggacgt 
D50482 atgagcacaaatcctaaacctcaaagaaaaaccaaacgtaacaccaaccgccgcccacaggacgt 
D50483 atgagcacgaatcctaaacctcaaagaaaaaccaaacgtaacaccaaccgccgcccacaggacgt 
D50484 atgagcacaaatcctaaacctcaaagacaaaccaaacgtaacaccaaccgccgcccacaggacgt 
D30613 · atgagcacaaatccaaaaccccaaagaaaaatcaaacgtaacaccaaccgccgcccacaggacgt
PQE30CORE caagt|cccgggcggtggtcaaatcgtt|gtggagtttac4|tgttgccgcccaggggccccaggt 
D50480 caagttcccgggcggtggtcagatcgttggtggagtttacctgttgccgcgcaggggccccaggt 
D50481 caagttcccgggcggtggtcagatcgttggtggagtttacctgttgccgcgcaggggccccaggt 
D50482 caagttcccgggcggtggtcagatcgttggtggagtttacctgttgccgcgcaggggccccaggt 
D50483 caagttcccgggcggtggtcagatcgttggtggagtttacctgttgccgcgcaggggccccaggt 
D50484 caagttcccgggcggtggtcagatcgttggtggagtttacctgttgccgcgcaggggccccaggt 
D30613 taagttcccgggcggtggtcagatcgttggtggagtttacctgttgccgcgcaggggccccaggt
PQE30CORE tgggtgtgcgcgcaaataggaaaacttccgaccggtcccaacBtcgtgaaaggcgacaacctatc 
D50480 tgggtgtgcgcgcgactaggaagacttccgagcggtcgcaacctcgtggaaggcgacaacctatc 
D50481 tgggtgtgcgcgcgactaggaagacttccgagcggtcgcaacctcgtggaaggcgacaacctatc 
D50482 tgggtgtgcgcgcgactaggaagacttccgagcggtcgcaacctcgtggaaggcgacaacctatc 
D50483 tgggtgtgcgcgcgactaggaagacttccgagcggtcgcaacctcgtggaaggcgacaacctatc 
D50484 tgggtgtgcgcgcgactaggaagacttccgagcggtcgcaacctcgtggaaggcgacaacctatc 
D30613 tgggtgtgcgcgcgactaggaagacttccgagcggccgcaacctcgtggaaggcgacaacctatc
PQE30CORE cccaaggctcgccggcccgagggcagagcctgggctcatcccgggtatccctggcctctctacag 
D5 0 4 8 0 cccaaggctcgccggcccgagggcagggcctgggctcagcccgggtacccttggcccctctat;gg 
D50481 cccaaggctcgccagcccgagggcagggcctgggctcagcccgggtacccttggcccctctatgg 
D50482 cccaaggttcgccggtccgagggcaggacctgggctcagcccgggtacccttggcccctctatgg 
D50483 cccaaggctcgccggcccgagggcagggcctgggctcagcccgggtacccttggcccctctatgg 
D50484 cccaaggttcgccggtccgagggcaggacctgggctcagcccgggtacccttggcccctctatgg 
D30613 cccaaggctcgccaacccgagggtagggcctgggctcagcccgggtacccttggcccctctatgg
PQE30CORE caatgagggcatggggtgggcaggatggctcctgtcaccccatggctctcggcctaattggggcc 
D50480 caatgagggcttagggtgggcaggatggctcctgtcaccccgcggctcccggcctagttggggcc 
D50481 caatgagggcatggggtgggcaggatggctcctgtcaccccgcggctctcggcctagttggggcc 
D50482 caatgagggtctggggtgggcaggatggctcctgtcaccccggggctctcggtctagttggggcc 
D50483 caatgagggcttagggtgggcaggatggctcctgtcaccccgcggctcccggcctagttggggcc 
D50484 caacgagggtctggggtgggcaggatggctcctgtcaccccgtggctctcggtctaattggggcc 
D30613 caatgagggcttggggtgggcaggatggctcctgtcaccGcgcggctcccggcctagttggggcc
PQE30CORE ccacagacccccggcatacgtcccgcaat§tgggtaaggtcat§aataccctcaH|9<^59Bit§ 
D50480 ccacggacccccggcgtaggtcgcgtaacttgggtaaggtcatcgataccctcacatgcggcttc 
D50481 ccacggacccccggcgtaggtcgcgtaatttgggtaaggtcatcgataccctcacatgcgggttc 
D50482 ccacggacccccggcgtaggtcgcgtaatttgggtaaggtcatcgatacccttacatgcgggttc 
D50483 ccacggacccccggcgtaggtcgcgtaacttgggtaaggtcatcgataccctcacatgcggcttc 
D50484 ccacggacccccggcgtaggtcgcgtaatttgggtaaggtcatcgatacccttacatgcgggttc 
D30613 ccacggacccccggcgtaggtcgcgtaatttgggtaaggtcatcgataccctcacatgcggcttc
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PQE30CORE §ccgaactcatggggtatattccJctttt§gg0cccccccta(ggggcgtJ§ccagggccccggJ 
D50480 gccgacctcatggggtacattccgctcgtcggcgcccccttgggaggcgctgccagggccctggc 
D50481 gccgacctcatggggtacattccgctcgtcggcgcccccctagggggcgcttccagggccctggc 
D5 0 4 8 2 gccgacctcatggggtacattcccgtcgtcggcccccccctagggggcgttgccagggccctggc 
D50483 gccgacctcatggggtacattccgctcgtcggcgcccccttgggaggcactgccagggccctggc 
D50484 gccgacctcatggggtacattccggtcgtcggcccccccctagggggcgttgccagggccctggc 
D3 0 613 gccgacctcatggggtacattccgctcgtcggcgcccccctagggggcgctgccagggctctagc
PQE30CORE JcacggjBIttcgggttJt------------------------------------------------
D50480 gcatggcgtccgggttctggaagacggcgtgaactatgcaacagggaatctgcccggttgctcttt
D50481 acatggtgtccgggttctggaggacggcgtgaactatgcaacagggaatctgcccggttgctcttt
D50482 gcatggtgtccgggttctggaggtcggcgtgaactacgcaacagggaatcttcccggttgctcttt
D50483 gcatggcgtccgggttctggaagacggcgtgaactatgcaacagggaatctgcccggttgctcttt
D50484 gcatggtgtccgggttctggaggtcggcgtgaactatgcaacagggaatcttcccggttgctcttt
D30613 gcatggcgtccgggttctggaggacggcgtgaactatgcaacagggaatctgcctggttgctcctt
PQE30CORE
D50480
D50481
D50482
D50483
D50484
D30613
ctctatcttcctc
ctctatcttcctc
ctctatcttcctc
ctctatcttcctc
ctctatcttcctc
ttctatcttcctt
The unclear bases were highlighted with green, the letters other than bases
mean;
w is A or T 
s is G or C 
k is G or T 
r is A or G 
y is C or T 
m is C or A 
n is any base
The bases in lb isolates which are different than the bases in our clone are 
highlighted with yellow.
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Alignment of our core antigen with other core antigens used in commercial 
kits (Chiron and Abbot, third generation)
APPENDIX C:
HCVCORE BU MSTNPKPQRKNKRNTNRRPQDVKFPGGGQIVGGVYLLPPRGPRLGVRANRKTSDRSQPRER
Abbot -..I.....T .......................... AA...... RT--- E.... G.
Chiron -......K................. ■...........R........ T--- E.... G.
HCVCORE BU RQPIPKARRPEGRAWAHPGYPWPLYSNEGMGWAGWLLSPHGSRPNWGPTDPRHTSRNLGK
Abbot .E___V..... T.RQ....... G...C..R..... R___ S...... RR.... -
Chiron ............T..Q..T.... G...C........ R--- S...... RR.... -
HCVCORE BU
Abbot
Chiron
VINTLTCGFPELMGYIPLFGPPLWGVARAPGHGVRV
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Sample Calculation:
1 . Negative Control: Calculate the mean absorbance of the replicates of the negative 
control serum (EN);
Well 1= 0,164; Well 2 = 0,181, Well 3= 0,173 
Mean Absorbance (A405) of Negative Control Serum
KO, 164+0.181+0.173)/3 
=0.173
2 . Relative Value of the Sample: Relative value of the sample is calculated by 
dividing the absorbance of the samples with the mean absorbance of the negative 
control sample.
A405 of sample:
Well 1=0.165 
Well 2= 0.132
Mean A450 of the Sample = 0,149 
Relative Value of the Sample
= Mean A405 of the Sample/ Mean Absorbance of Negative Control 
= 0,149/0.173 = 0.9
3. Cut-Off Value: The samples with relative values 2.5 and more are considered as 
positive, and the samples with relative values 1.5 and less are considered as 
negative.
Relative Value of Sample = 0.9 < 1.5 therefore the sample is negative.
APPENDIX D:
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